Adverse Event,Category,Trial Id,URL,Condition,Intervention,Total -affected,Total -at risk,Serious/Other,Arm#,Arm Title,Arm-affected,Arm-at risk
allergic_reaction,Immune_system_disorders,NCT00001962,https://clinicaltrials.gov/show/NCT00001962,Aplastic_Anemia|Pure_Red_Cell_Aplasia|Diamond_Blackfan_Anemia|,Daclizumab,7,100,other_events,arm0,Daclizumab Hematologic Response,7,100
Allergic_reaction,Immune_system_disorders,NCT00003389,https://clinicaltrials.gov/show/NCT00003389,Lymphoma,Doxorubicin|Bleomycin|Vinblastine|Dacarbazine|Vincristine|Mechlorethamine|Etoposide|Prednisone|Cyclophosphamide|Radiotherapy|,3,422,serious_events,arm1,Arm B (Stanford V),3,422
Allergic_reaction,Immune_system_disorders,NCT00003896,https://clinicaltrials.gov/show/NCT00003896,Fallopian_Tube_Cancer|Ovarian_Cancer|Peritoneal_Cavity_Cancer|,cisplatin|liposomal_doxorubicin|paclitaxel|,5,61,other_events,arm0,Paclitaxel/CDDP/Liposomal Doxorubicin,5,61
Allergic_reaction,Immune_system_disorders,NCT00004859,https://clinicaltrials.gov/show/NCT00004859,Lung_Cancer,carboplatin|paclitaxel|thalidomide|radiation_therapy|,29,577,serious_events,arm1,Arm B (Paclitaxel + Carboplatin + Radiation + Thalidomide),13,288
Allergic_reaction,Immune_system_disorders,NCT00004859,https://clinicaltrials.gov/show/NCT00004859,Lung_Cancer,carboplatin|paclitaxel|thalidomide|radiation_therapy|,29,577,serious_events,arm0,Arm A (Paclitaxel + Carboplatin + Radiation ),16,289
Allergic_Reaction,General_disorders,NCT00004888,https://clinicaltrials.gov/show/NCT00004888,Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,pegylated_liposomal_doxorubicin_hydrochloride|docetaxel|trastuzumab|laboratory_biomarker_analysis|,11,89,other_events,arm1,Arm II: Doxorubicin Taxotere and Herceptin,8,48
Allergic_Reaction,General_disorders,NCT00004888,https://clinicaltrials.gov/show/NCT00004888,Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,pegylated_liposomal_doxorubicin_hydrochloride|docetaxel|trastuzumab|laboratory_biomarker_analysis|,11,89,other_events,arm0,Arm I: Doxorubicin and Taxotere,3,41
Allergic_reaction,Immune_system_disorders,NCT00006721,https://clinicaltrials.gov/show/NCT00006721,Lymphoma,rituximab|cyclophosphamide|doxorubicin_hydrochloride|prednisone|vincristine_sulfate|tositumomab_and_iodine_I_131_tositumomab|,50,276,other_events,arm1,CHOP + Rituximab,49,263
Allergic_reaction,Immune_system_disorders,NCT00006721,https://clinicaltrials.gov/show/NCT00006721,Lymphoma,rituximab|cyclophosphamide|doxorubicin_hydrochloride|prednisone|vincristine_sulfate|tositumomab_and_iodine_I_131_tositumomab|,50,276,other_events,arm0,CHOP Only,1,13
Allergic_reaction,Immune_system_disorders,NCT00008138,https://clinicaltrials.gov/show/NCT00008138,Fallopian_Tube_Cancer|Ovarian_Cancer|Peritoneal_Cavity_Cancer|,carboplatin|paclitaxel|debulking_surgery|,4,58,other_events,arm0,Neoadjuvant Paclitaxel (IV) + Carboplatin (V),4,58
Allergic_Reaction,Immune_system_disorders,NCT00010257,https://clinicaltrials.gov/show/NCT00010257,Thymoma|Thymic_Carcinoma|,carboplatin|paclitaxel|,2,42,serious_events,arm1,Thymic Carcinoma,1,21
Allergic_Reaction,Immune_system_disorders,NCT00010257,https://clinicaltrials.gov/show/NCT00010257,Thymoma|Thymic_Carcinoma|,carboplatin|paclitaxel|,2,42,other_events,arm1,Thymic Carcinoma,1,21
Allergic_Reaction,Immune_system_disorders,NCT00022659,https://clinicaltrials.gov/show/NCT00022659,Primary_Peritoneal_Cavity_Cancer|Recurrent_Ovarian_Epithelial_Cancer|Stage_IV_Ovarian_Epithelial_Cancer|,bevacizumab|laboratory_biomarker_analysis|,3,124,other_events,arm0,Bevacizumab,2,62
Allergic_Reaction,Immune_system_disorders,NCT00022659,https://clinicaltrials.gov/show/NCT00022659,Primary_Peritoneal_Cavity_Cancer|Recurrent_Ovarian_Epithelial_Cancer|Stage_IV_Ovarian_Epithelial_Cancer|,bevacizumab|laboratory_biomarker_analysis|,3,124,serious_events,arm0,Bevacizumab,1,62
Allergic_Reaction,Immune_system_disorders,NCT00025155,https://clinicaltrials.gov/show/NCT00025155,Primary_Peritoneal_Cavity_Cancer|Recurrent_Ovarian_Epithelial_Cancer|,ixabepilone,3,49,other_events,arm0,Treatment (Ixabepilone),3,49
Allergic_Reaction,Immune_system_disorders,NCT00025233,https://clinicaltrials.gov/show/NCT00025233,Cervical_Squamous_Cell_Carcinoma|Recurrent_Cervical_Cancer|,bevacizumab|laboratory_biomarker_analysis|,1,46,other_events,arm0,Bevacizumab,1,46
Allergic_reaction,General_disorders,NCT00038948,https://clinicaltrials.gov/show/NCT00038948,Renal_Transplantation,Sirolimus|tacrolimus|Cyclosporine_A|,1,551,serious_events,arm0,SRL Conversion in Stable Renal Transplant Recipients,1,551
Allergic_reaction,Immune_system_disorders,NCT00040937,https://clinicaltrials.gov/show/NCT00040937,Multiple_Myeloma,filgrastim|sargramostim|cyclophosphamide|dexamethasone|melphalan|prednisone|thalidomide|peripheral_blood_stem_cell_transplantation|,6,105,other_events,arm1,Autologous PBSCT,6,105
Allergic_reaction,Immune_system_disorders,NCT00041132,https://clinicaltrials.gov/show/NCT00041132,Lymphoma,filgrastim|rituximab|cyclophosphamide|cytarabine|dexamethasone|doxorubicin|leucovorin|methotrexate|vincristine|,5,49,other_events,arm0,Hyper-CVAD + MTX/Ara-C + Rituximab,5,49
Allergic_Reaction,Immune_system_disorders,NCT00042939,https://clinicaltrials.gov/show/NCT00042939,Pancreatic_Cancer,cetuximab|docetaxel|irinotecan_hydrochloride|,1,46,serious_events,arm0,Arm A: Irinotecan/Docetaxel,1,46
Allergic_reaction,Immune_system_disorders,NCT00045630,https://clinicaltrials.gov/show/NCT00045630,Bladder_Cancer|Transitional_Cell_Cancer_of_the_Renal_Pelvis_and_Ureter|Urethral_Cancer|,carboplatin|gemcitabine|paclitaxel|surgery|,6,74,other_events,arm0,Gemcitabine Paclitaxel Carboplatin Followed by Surgery,6,74
Allergic_reaction,Immune_system_disorders,NCT00047320,https://clinicaltrials.gov/show/NCT00047320,Brain_Tumor|Central_Nervous_System_Tumors|Childhood_Germ_Cell_Tumor|,carboplatin|etoposide|ifosfamide|thiotepa|adjuvant_therapy|conventional_surgery|neoadjuvant_therapy|peripheral_blood_stem_cell_transplantation|radiation_therapy|,2,101,other_events,arm0,Radiation Therapy (CR From Induction),2,101
allergic_reaction,Immune_system_disorders,NCT00049257,https://clinicaltrials.gov/show/NCT00049257,Prostate_Cancer,carboplatin|paclitaxel|,5,58,other_events,arm0,Carboplatin Paclitaxel,5,58
Allergic_reaction,Immune_system_disorders,NCT00049543,https://clinicaltrials.gov/show/NCT00049543,Adenocarcinoma_of_the_Lung|Adenosquamous_Cell_Lung_Cancer|Bronchoalveolar_Cell_Lung_Cancer|Large_Cell_Lung_Cancer|Squamous_Cell_Lung_Cancer|Stage_IB_Non-small_Cell_Lung_Cancer|Stage_IIA_Non-small_Cell_Lung_Cancer|Stage_IIB_Non-small_Cell_Lung_Cancer|Stage_IIIA_Non-small_Cell_Lung_Cancer|,gefitinib|placebo|laboratory_biomarker_analysis|,1,243,serious_events,arm1,Arm II (Placebo),1,243
Allergic_reaction,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,16,1180,other_events,arm0,Weekly Paclitaxel (WP),4,297
Allergic_reaction,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,16,1180,other_events,arm1,Docetaxel and Capecitabine (DX),6,293
Allergic_reaction,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,16,1180,serious_events,arm0,Weekly Paclitaxel (WP),2,297
Allergic_reaction,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,16,1180,serious_events,arm1,Docetaxel and Capecitabine (DX),4,293
Allergic_reaction,Immune_system_disorders,NCT00057811,https://clinicaltrials.gov/show/NCT00057811,Childhood_Burkitt_Lymphoma|Childhood_Diffuse_Large_Cell_Lymphoma|Childhood_Immunoblastic_Large_Cell_Lymphoma|Stage_I_Childhood_Large_Cell_Lymphoma|Stage_I_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_II_Childhood_Large_Cell_Lymphoma|Stage_II_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_III_Childhood_Large_Cell_Lymphoma|Stage_III_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_IV_Childhood_Large_Cell_Lymphoma|Stage_IV_Childhood_Small_Noncleaved_Cell_Lymphoma|Untreated_Childhood_Acute_Lymphoblastic_Leukemia|,doxorubicin_hydrochloride|cyclophosphamide|methotrexate|rasburicase|leucovorin_calcium|prednisone|methylprednisolone|filgrastim|rituximab|cytarabine|etoposide|vincristine_sulfate|hydrocortisone_sodium_succinate|laboratory_biomarker_analysis|,7,88,other_events,arm0,Group B (Chemotherapy Protective Therapy Monoclonal Antib.),5,46
Allergic_reaction,Immune_system_disorders,NCT00057811,https://clinicaltrials.gov/show/NCT00057811,Childhood_Burkitt_Lymphoma|Childhood_Diffuse_Large_Cell_Lymphoma|Childhood_Immunoblastic_Large_Cell_Lymphoma|Stage_I_Childhood_Large_Cell_Lymphoma|Stage_I_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_II_Childhood_Large_Cell_Lymphoma|Stage_II_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_III_Childhood_Large_Cell_Lymphoma|Stage_III_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_IV_Childhood_Large_Cell_Lymphoma|Stage_IV_Childhood_Small_Noncleaved_Cell_Lymphoma|Untreated_Childhood_Acute_Lymphoblastic_Leukemia|,doxorubicin_hydrochloride|cyclophosphamide|methotrexate|rasburicase|leucovorin_calcium|prednisone|methylprednisolone|filgrastim|rituximab|cytarabine|etoposide|vincristine_sulfate|hydrocortisone_sodium_succinate|laboratory_biomarker_analysis|,7,88,other_events,arm1,Group C (Chemotherapy Monoclonal Antibody Therapy),2,42
Allergic_reaction,Immune_system_disorders,NCT00060346,https://clinicaltrials.gov/show/NCT00060346,Lymphoma,rituximab|cyclophosphamide|Doxorubicin|Prednisone|Vincristine|,1,16,serious_events,arm0,Rituximab + CHOP,1,16
Allergic_reaction,Immune_system_disorders,NCT00064350,https://clinicaltrials.gov/show/NCT00064350,Lung_Cancer,Sorafenib|Placebo|,2,333,serious_events,arm0,Induction: Sorafenib,2,333
ALLERGIC_REACTION,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,32,1024,other_events,arm0,Interferon Alfa,1,200
ALLERGIC_REACTION,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,32,1024,other_events,arm2,Interferon Alfa and Temsirolimus,11,208
ALLERGIC_REACTION,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,32,1024,serious_events,arm2,Interferon Alfa and Temsirolimus,1,208
ALLERGIC_REACTION,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,32,1024,other_events,arm1,Temsirolimus,18,208
ALLERGIC_REACTION,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,32,1024,serious_events,arm0,Interferon Alfa,1,200
Allergic_reaction,Immune_system_disorders,NCT00066573,https://clinicaltrials.gov/show/NCT00066573,Breast_Cancer,anastrozole|exemestane|,1,3761,serious_events,arm0,Exemestane,1,3761
Allergic_reaction,General_disorders,NCT00067808,https://clinicaltrials.gov/show/NCT00067808,Myelodysplastic_Syndrome|Chronic_Myelomonocytic_Leukemia|,Decitabine|Decitabine|Decitabine|,3,107,other_events,arm2,Decitabine 20 mg/m2 SQ,1,14
Allergic_reaction,General_disorders,NCT00067808,https://clinicaltrials.gov/show/NCT00067808,Myelodysplastic_Syndrome|Chronic_Myelomonocytic_Leukemia|,Decitabine|Decitabine|Decitabine|,3,107,serious_events,arm1,Decitabine 20 mg/m2 IV,2,93
Allergic_reaction,Immune_system_disorders,NCT00071981,https://clinicaltrials.gov/show/NCT00071981,Melanoma_(Skin),incomplete_Freund's_adjuvant|melanoma_helper_peptide_vaccine|multi-epitope_melanoma_peptide_vaccine|sargramostim|tetanus_peptide_melanoma_vaccine|,1,38,serious_events,arm1,Arm II (12MP/Tet),1,38
Allergic_reaction,Immune_system_disorders,NCT00072176,https://clinicaltrials.gov/show/NCT00072176,Endometrial_Adenocarcinoma|Endometrial_Adenosquamous_Cell_Carcinoma|Endometrial_Clear_Cell_Carcinoma|Endometrial_Papillary_Serous_Carcinoma|Recurrent_Endometrial_Carcinoma|Stage_IIIA_Endometrial_Carcinoma|Stage_IIIB_Endometrial_Carcinoma|Stage_IIIC_Endometrial_Carcinoma|Stage_IVA_Endometrial_Carcinoma|Stage_IVB_Endometrial_Carcinoma|,temsirolimus|laboratory_biomarker_analysis|,3,60,other_events,arm0,Group A,2,33
Allergic_reaction,Immune_system_disorders,NCT00072176,https://clinicaltrials.gov/show/NCT00072176,Endometrial_Adenocarcinoma|Endometrial_Adenosquamous_Cell_Carcinoma|Endometrial_Clear_Cell_Carcinoma|Endometrial_Papillary_Serous_Carcinoma|Recurrent_Endometrial_Carcinoma|Stage_IIIA_Endometrial_Carcinoma|Stage_IIIB_Endometrial_Carcinoma|Stage_IIIC_Endometrial_Carcinoma|Stage_IVA_Endometrial_Carcinoma|Stage_IVB_Endometrial_Carcinoma|,temsirolimus|laboratory_biomarker_analysis|,3,60,other_events,arm1,Group B,1,27
Allergic_Reaction,Immune_system_disorders,NCT00073307,https://clinicaltrials.gov/show/NCT00073307,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,1,452,serious_events,arm2,Sorafenib (Nexavar BAY43-9006)-30Jun2008,1,452
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,other_events,arm2,Dexamethasone High Dose Methotrexate (IM) < 10 Years,1,203
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,other_events,arm1,Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old,2,239
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,serious_events,arm5,Prednisone Capezzi Methotrexate >= 10 Years,1,555
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,serious_events,arm1,Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old,1,239
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,serious_events,arm0,Dexamethasone and Capizzi Methotrexate Patients < 10 Years,1,215
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,other_events,arm4,Prednisone Capizzi Methotrexate <10 Years,2,207
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,other_events,arm5,Prednisone Capezzi Methotrexate >= 10 Years,9,555
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,other_events,arm6,Predisone and High Dose Methotrexate < 10 Yrs Old,1,203
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,other_events,arm8,Dexamethasone High Dose Methotrexate (Non Randomly Assigned),2,84
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,other_events,arm0,Dexamethasone and Capizzi Methotrexate Patients < 10 Years,1,215
Allergic_reaction,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,29,3277,other_events,arm7,Prenisone and High Dose Methotrexate >=10 Years,8,562
Allergic_reaction,Immune_system_disorders,NCT00077207,https://clinicaltrials.gov/show/NCT00077207,Brain_Tumor|Central_Nervous_System_Tumor|,carboplatin|temozolomide|vincristine_sulfate|,7,64,other_events,arm0,Treatment (Carboplatin Vincristine Sulfate Temozolomide),7,64
Allergic_reaction,Immune_system_disorders,NCT00077376,https://clinicaltrials.gov/show/NCT00077376,HER2-positive_Breast_Cancer|Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|carboplatin|laboratory_biomarker_analysis|,10,118,serious_events,arm0,Trastuzumab/Ixabepilone/Carboplatin,2,59
Allergic_reaction,Immune_system_disorders,NCT00077376,https://clinicaltrials.gov/show/NCT00077376,HER2-positive_Breast_Cancer|Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|carboplatin|laboratory_biomarker_analysis|,10,118,other_events,arm0,Trastuzumab/Ixabepilone/Carboplatin,8,59
Allergic_Reaction,Immune_system_disorders,NCT00079040,https://clinicaltrials.gov/show/NCT00079040,Extensive_Stage_Small_Cell_Lung_Cancer,cisplatin|etoposide|bevacizumab|laboratory_biomarker_analysis|,1,64,serious_events,arm0,Cisplatin Etoposide Bevacizumab,1,64
Allergic_Reaction,Immune_system_disorders,NCT00079326,https://clinicaltrials.gov/show/NCT00079326,HER2-positive_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|laboratory_biomarker_analysis|,3,39,other_events,arm0,All Study Participants,3,39
Allergic_reaction,Immune_system_disorders,NCT00081289,https://clinicaltrials.gov/show/NCT00081289,Colorectal_Cancer,Radiation_Therapy|Capecitabine_1650_mg/m^2/day|Capecitabine_1200_mg/m^2/day|Irinotecan|Oxaliplatin|Surgery|Folinic_Acid|Fluorouracil|Oxaliplatin|,3,69,other_events,arm1,Neoadjuvant Chemoradiation With Oxaliplatin,3,69
Allergic_reaction,Immune_system_disorders,NCT00083174,https://clinicaltrials.gov/show/NCT00083174,Breast_Cancer,exemestane,1,2240,serious_events,arm0,Exemestane,1,2240
Allergic_reaction,Immune_system_disorders,NCT00085631,https://clinicaltrials.gov/show/NCT00085631,Cervical_Cancer,cisplatin|hyperthermia_treatment|brachytherapy|external_beam_radiation_therapy|,2,202,other_events,arm0,Overall Study,1,101
Allergic_reaction,Immune_system_disorders,NCT00085631,https://clinicaltrials.gov/show/NCT00085631,Cervical_Cancer,cisplatin|hyperthermia_treatment|brachytherapy|external_beam_radiation_therapy|,2,202,serious_events,arm0,Overall Study,1,101
Allergic_reaction,General_disorders,NCT00086346,https://clinicaltrials.gov/show/NCT00086346,Liver_Transplantation,Sirolimus_(Rapamune)|Cyclosporine_or_Tacrolimus|,1,389,serious_events,arm0,Sirolimus (SRL) Conversion,1,389
Allergic_reaction,Immune_system_disorders,NCT00087139,https://clinicaltrials.gov/show/NCT00087139,Adenocarcinoma_of_the_Prostate|Recurrent_Prostate_Cancer|Stage_IV_Prostate_Cancer|,ixabepilone,1,123,serious_events,arm0,Ixabepilone,1,123
Allergic_reaction,Immune_system_disorders,NCT00088881,https://clinicaltrials.gov/show/NCT00088881,Contiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Extranodal_Marginal_Zone_B-cell_Lymphoma_of_Mucosa-associated_Lymphoid_Tissue|Nodal_Marginal_Zone_B-cell_Lymphoma|Noncontiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Splenic_Marginal_Zone_Lymphoma|Stage_I_Adult_Diffuse_Large_Cell_Lymphoma|Testicular_Lymphoma|WaldenstrÕ_m_Macroglobulinemia|,rituximab|prednisone|cyclophosphamide|doxorubicin|vincristine|indium_In_111_ibritumomab_tiuxetan|radiation_therapy|positron_emission_tomography|,1,62,serious_events,arm0,Step 1 - R-CHOP,1,62
Allergic_reaction,Immune_system_disorders,NCT00089297,https://clinicaltrials.gov/show/NCT00089297,Head_and_Neck_Cancer,Cetuximab|Carboplatin|Paclitaxel|Radiation_therapy|,3,70,serious_events,arm0,Cetuximab/Paclitaxel/Carboplatin,3,70
Allergic_reaction,Immune_system_disorders,NCT00089544,https://clinicaltrials.gov/show/NCT00089544,Recurrent_Adult_Soft_Tissue_Sarcoma|Stage_I_Adult_Soft_Tissue_Sarcoma|Stage_II_Adult_Soft_Tissue_Sarcoma|Stage_III_Adult_Soft_Tissue_Sarcoma|,doxorubicin_hydrochloride|ifosfamide|dacarbazine|filgrastim|radiation_therapy|thalidomide|therapeutic_conventional_surgery|laboratory_biomarker_analysis|,1,15,other_events,arm0,Cohort A (Chemotherapy Radiation Thalidomide Surgery),1,15
allergic_reaction,Immune_system_disorders,NCT00090610,https://clinicaltrials.gov/show/NCT00090610,Ovarian_Cancer,Docetaxel|Carboplatin|,2,149,serious_events,arm1,Arm2,1,74
allergic_reaction,Immune_system_disorders,NCT00090610,https://clinicaltrials.gov/show/NCT00090610,Ovarian_Cancer,Docetaxel|Carboplatin|,2,149,serious_events,arm0,Arm 1,1,75
Allergic_reaction,Immune_system_disorders,NCT00094900,https://clinicaltrials.gov/show/NCT00094900,Inflammation|Familial_Mediterranean_Fever|Still's_Disease_Adult-Onset|,IL-1_Trap,1,11,other_events,arm0,IL-1 Trap,1,11
Allergic_reaction,Immune_system_disorders,NCT00096135,https://clinicaltrials.gov/show/NCT00096135,Leukemia,filgrastim|cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|etoposide|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|therapeutic_hydrocortisone|vincristine_sulfate|radiation_therapy|,2,166,other_events,arm1,Testicular Relapse Patients (Combination Chemotherapy),1,42
Allergic_reaction,Immune_system_disorders,NCT00096135,https://clinicaltrials.gov/show/NCT00096135,Leukemia,filgrastim|cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|etoposide|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|therapeutic_hydrocortisone|vincristine_sulfate|radiation_therapy|,2,166,other_events,arm0,CNS Patients - Treatment (Combination Chemotherapy),1,124
allergic_reaction,General_disorders,NCT00096356,https://clinicaltrials.gov/show/NCT00096356,Breast_Cancer|Fatigue|,CoQ10_&_Vitamin_E|Placebo_&_Vitamin_E|,1,100,serious_events,arm0,Arm 1 - CoQ10 & Vitamin E,1,100
Allergic_reaction,Immune_system_disorders,NCT00098865,https://clinicaltrials.gov/show/NCT00098865,Central_Nervous_System_Tumor_Pediatric|Neuroblastoma|,temozolomide|thalidomide|,1,15,serious_events,arm0,Thalidomide and Temzolomide,1,15
Allergic_reaction,Immune_system_disorders,NCT00098787,https://clinicaltrials.gov/show/NCT00098787,Colorectal_Cancer,bevacizumab|fluorouracil|irinotecan_hydrochloride|leucovorin_calcium|Oxaliplatin|,10,143,other_events,arm1,High TS: FOLFOX/Bev,3,73
Allergic_reaction,Immune_system_disorders,NCT00098787,https://clinicaltrials.gov/show/NCT00098787,Colorectal_Cancer,bevacizumab|fluorouracil|irinotecan_hydrochloride|leucovorin_calcium|Oxaliplatin|,10,143,other_events,arm0,High TS: IROX/Bev,7,70
Allergic_reaction,Immune_system_disorders,NCT00103207,https://clinicaltrials.gov/show/NCT00103207,Lung_Cancer,cetuximab,5,144,other_events,arm0,Cetuximab,4,72
Allergic_reaction,Immune_system_disorders,NCT00103207,https://clinicaltrials.gov/show/NCT00103207,Lung_Cancer,cetuximab,5,144,serious_events,arm0,Cetuximab,1,72
Allergic_reaction,General_disorders,NCT00106353,https://clinicaltrials.gov/show/NCT00106353,Adenocarcinoma|Neoplasms|,Torisel,2,10,other_events,arm2,Temsirolimus 75 mg/m^2: Part 1,1,3
Allergic_reaction,General_disorders,NCT00106353,https://clinicaltrials.gov/show/NCT00106353,Adenocarcinoma|Neoplasms|,Torisel,2,10,other_events,arm3,Temsirolimus 150 mg/m^2: Part 1,1,7
Allergic_reaction,Immune_system_disorders,NCT00106938,https://clinicaltrials.gov/show/NCT00106938,Carotid_Artery_Disease|Carotid_Stenosis|Stroke|Atherosclerosis|,Carotid_artery_stenting_with_filter_(interventional)|Carotid_artery_endarterectomy_(surgical)|,2,814,serious_events,arm0,CAS Group,2,814
Allergic_reaction,Immune_system_disorders,NCT00110019,https://clinicaltrials.gov/show/NCT00110019,Mucosal_Melanoma|Recurrent_Melanoma|Stage_IIIA_Skin_Melanoma|Stage_IIIB_Skin_Melanoma|Stage_IIIC_Skin_Melanoma|Stage_IV_Skin_Melanoma|,Carboplatin|Laboratory_Biomarker_Analysis|Paclitaxel|Pharmacological_Study|Placebo|Sorafenib_Tosylate|,31,790,serious_events,arm1,Arm II (Carboplatin + Paclitaxel+Placebo),11,397
Allergic_reaction,Immune_system_disorders,NCT00110019,https://clinicaltrials.gov/show/NCT00110019,Mucosal_Melanoma|Recurrent_Melanoma|Stage_IIIA_Skin_Melanoma|Stage_IIIB_Skin_Melanoma|Stage_IIIC_Skin_Melanoma|Stage_IV_Skin_Melanoma|,Carboplatin|Laboratory_Biomarker_Analysis|Paclitaxel|Pharmacological_Study|Placebo|Sorafenib_Tosylate|,31,790,serious_events,arm0,Arm I (Carboplatin + Paclitaxel + Sorafenib),20,393
allergic_reaction,Immune_system_disorders,NCT00110994,https://clinicaltrials.gov/show/NCT00110994,Cancer|Melanoma|,Sorafenib_(Nexavar_BAY43-9006)|Placebo|Dacarbazine|,3,51,other_events,arm0,Sorafenib (Nexavar BAY43-9006) + Dacarbazine,3,51
allergic_reaction,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,24,536,serious_events,arm1,Carboplatin/Paclitaxel (C/P),2,134
allergic_reaction,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,24,536,serious_events,arm0,Sorafenib (Nexavar BAY43-9006),4,134
allergic_reaction,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,24,536,other_events,arm1,Carboplatin/Paclitaxel (C/P),10,134
allergic_reaction,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,24,536,other_events,arm0,Sorafenib (Nexavar BAY43-9006),8,134
Allergic_reaction,Immune_system_disorders,NCT00113217,https://clinicaltrials.gov/show/NCT00113217,Renal_Cell_Carcinoma|Kidney_Cancer|,Bevacizumab,2,50,serious_events,arm0,Bevacizumab,2,50
Allergic_reaction,Immune_system_disorders,NCT00113386,https://clinicaltrials.gov/show/NCT00113386,Lung_Cancer,filgrastim|pegfilgrastim|cisplatin|docetaxel|adjuvant_therapy|conventional_surgery|neoadjuvant_therapy|radiation_therapy|,1,9,other_events,arm0,Preoperative Cisplatin/Docetaxel,1,9
Allergic_reaction,Immune_system_disorders,NCT00113399,https://clinicaltrials.gov/show/NCT00113399,Head_and_Neck_Cancer,filgrastim|cisplatin|docetaxel|fluorouracil|paclitaxel|radiation_therapy|,1,7,serious_events,arm1,Chemotherapy Alone,1,7
Allergic_reaction,Immune_system_disorders,NCT00117156,https://clinicaltrials.gov/show/NCT00117156,Lymphoma_Non-Hodgkin|MALT_Lymphoma|,Fludarabine|Rituximab|,6,52,other_events,arm0,Fludarabine and Rituximab,5,26
Allergic_reaction,Immune_system_disorders,NCT00117156,https://clinicaltrials.gov/show/NCT00117156,Lymphoma_Non-Hodgkin|MALT_Lymphoma|,Fludarabine|Rituximab|,6,52,serious_events,arm0,Fludarabine and Rituximab,1,26
allergic_reaction,Immune_system_disorders,NCT00117637,https://clinicaltrials.gov/show/NCT00117637,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006)|Interferon|,2,187,serious_events,arm1,Interferon Therapy in Period 1,1,90
allergic_reaction,Immune_system_disorders,NCT00117637,https://clinicaltrials.gov/show/NCT00117637,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006)|Interferon|,2,187,serious_events,arm0,Sorafenib 400 mg in Period 1,1,97
Allergic_reaction,Immune_system_disorders,NCT00119262,https://clinicaltrials.gov/show/NCT00119262,Male_Breast_Cancer|Stage_II_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|,doxorubicin_hydrochloride|cyclophosphamide|bevacizumab|paclitaxel|filgrastim|pegfilgrastim|radiation_therapy|tamoxifen_citrate|aromatase_inhibition_therapy|,4,103,serious_events,arm0,Arm A (ddBAC > BT > B),4,103
Allergic_Reaction,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,4,122,other_events,arm2,Group C-Bevacizumab + Capcitabine(18 Wks),1,41
Allergic_Reaction,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,4,122,other_events,arm3,Group D-bevacizumab + Capecitibine (24wks),2,40
Allergic_Reaction,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,4,122,other_events,arm1,Group B-Bevacizumab+Cyclophosphamide+Methotrexate,1,41
Allergic_reaction,Immune_system_disorders,NCT00126555,https://clinicaltrials.gov/show/NCT00126555,Recurrent_Skin_Cancer|Squamous_Cell_Carcinoma_of_the_Skin|,Gefitinib|Radiotherapy|Conventional_surgery|laboratory_biomarker_analysis|,2,22,other_events,arm0,Gefitinib Radiotherapy Surgery,2,22
allergic_reaction,General_disorders,NCT00128206,https://clinicaltrials.gov/show/NCT00128206,Tuberculosis,Isoniazid|Rifampin|,1,180,serious_events,arm1,Rifampin,1,180
Allergic_reaction,Immune_system_disorders,NCT00131937,https://clinicaltrials.gov/show/NCT00131937,Anaplastic_Large_Cell_Lymphoma|Angioimmunoblastic_T-cell_Lymphoma|Hepatosplenic_T-cell_Lymphoma|Peripheral_T-cell_Lymphoma|Recurrent_Adult_Diffuse_Large_Cell_Lymphoma|Recurrent_Adult_Immunoblastic_Large_Cell_Lymphoma|Recurrent_Adult_T-cell_Leukemia/Lymphoma|Recurrent_Cutaneous_T-cell_Non-Hodgkin_Lymphoma|,sorafenib_tosylate,1,14,other_events,arm0,Treatment (Sorafenib),1,14
Allergic_reaction,Immune_system_disorders,NCT00132691,https://clinicaltrials.gov/show/NCT00132691,Uveitis,fluocinolone_acetonide_intraocular_implant|oral_corticosteroid_with_immunosuppressive_agents_as_needed|,19,255,other_events,arm1,Systemic Therapy,9,126
Allergic_reaction,Immune_system_disorders,NCT00132691,https://clinicaltrials.gov/show/NCT00132691,Uveitis,fluocinolone_acetonide_intraocular_implant|oral_corticosteroid_with_immunosuppressive_agents_as_needed|,19,255,other_events,arm0,Flucinolone Acetonide Implant,10,129
Allergic_reaction,Immune_system_disorders,NCT00153816,https://clinicaltrials.gov/show/NCT00153816,Colorectal_Cancer|Polyps|Adenomas|,Calcium_Carbonate|Vitamin_D3|placebo|,2,415,serious_events,arm0,Full Factorial Placebo,2,415
Allergic_reaction,General_disorders,NCT00178464,https://clinicaltrials.gov/show/NCT00178464,Sickle_Cell_Disease,aspirin,1,11,other_events,arm0,Aspirin,1,11
Allergic_reaction,Immune_system_disorders,NCT00179309,https://clinicaltrials.gov/show/NCT00179309,Breast_Cancer,Docetaxel|PANVAC-V|PANVAC-F|Sargramostim|,3,25,other_events,arm0,Arm I - PANVAC + Docetaxel,3,25
Allergic_reaction,Immune_system_disorders,NCT00185211,https://clinicaltrials.gov/show/NCT00185211,Multiple_Sclerosis,Interferon_beta-1b_(Betaseron_BAY86-5046)|Interferon_beta-1b_(Betaseron_BAY86-5046)|,35,760,other_events,arm1,Initial Placebo,11,176
Allergic_reaction,Immune_system_disorders,NCT00185211,https://clinicaltrials.gov/show/NCT00185211,Multiple_Sclerosis,Interferon_beta-1b_(Betaseron_BAY86-5046)|Interferon_beta-1b_(Betaseron_BAY86-5046)|,35,760,other_events,arm0,Initial IFNB-1b (Interferon Beta-1b),23,292
Allergic_reaction,Immune_system_disorders,NCT00185211,https://clinicaltrials.gov/show/NCT00185211,Multiple_Sclerosis,Interferon_beta-1b_(Betaseron_BAY86-5046)|Interferon_beta-1b_(Betaseron_BAY86-5046)|,35,760,serious_events,arm0,Initial IFNB-1b (Interferon Beta-1b),1,292
Allergic_reaction,General_disorders,NCT00193180,https://clinicaltrials.gov/show/NCT00193180,Breast_Cancer,Imatinib|Docetaxel|,2,37,other_events,arm0,Docetaxel+Imatinib,2,37
Allergic_Reaction,Immune_system_disorders,NCT00193219,https://clinicaltrials.gov/show/NCT00193219,Colon_Cancer,Bevacizumab|Cetuximab|5-fluorouracil|Leucovorin|Oxaliplatin|,2,31,serious_events,arm0,Bevacizumab/Cetuximab/FOLFOX,2,31
Allergic_Reaction,Immune_system_disorders,NCT00193453,https://clinicaltrials.gov/show/NCT00193453,Lung_Cancer,Gemcitabine|Docetaxel|Cetuximab|,11,138,other_events,arm0,Intervention,8,69
Allergic_Reaction,Immune_system_disorders,NCT00193453,https://clinicaltrials.gov/show/NCT00193453,Lung_Cancer,Gemcitabine|Docetaxel|Cetuximab|,11,138,serious_events,arm0,Intervention,3,69
Allergic_reaction,Immune_system_disorders,NCT00193492,https://clinicaltrials.gov/show/NCT00193492,Lymphoma_Follicular,Bevacizumab|Rituximab|,10,60,other_events,arm1,Rituximab/Bevacizumab,2,29
Allergic_reaction,Immune_system_disorders,NCT00193492,https://clinicaltrials.gov/show/NCT00193492,Lymphoma_Follicular,Bevacizumab|Rituximab|,10,60,other_events,arm0,Rituximab,8,31
Allergic_Reaction,Immune_system_disorders,NCT00193596,https://clinicaltrials.gov/show/NCT00193596,Neoplasms_Unknown_Primary,Etoposide|Gemcitabine|Irinotecan|Paclitaxel|Carboplatin|,1,93,serious_events,arm0,Paclitaxel/Carboplatin/Etoposide/Gefitinib,1,93
Allergic_Reaction,Immune_system_disorders,NCT00193609,https://clinicaltrials.gov/show/NCT00193609,Neoplasms_Unknown_Primary,Oxaliplatin|Capecitabine|,3,48,other_events,arm0,Intervention,3,48
Allergic_reaction,General_disorders,NCT00224016,https://clinicaltrials.gov/show/NCT00224016,Detrusor_Hyperreflexia,Oxybutynin|Oxybutynin|,1,16,serious_events,arm1,Oral Oxybutynin,1,16
Allergic_Reaction,Immune_system_disorders,NCT00235989,https://clinicaltrials.gov/show/NCT00235989,Multiple_Sclerosis_Relapsing-Remitting,Interferon_beta_1b_(Betaseron_BAY86-5046)|Interferon_beta_1b_(Betaseron_BAY86-5046)|Interferon_beta_1b_(Betaseron_BAY86-5046)|Interferon_beta_1b_(Betaseron_BAY86-5046)|,6,55,other_events,arm3,ET: IFNB-1b 250 mcg => 500 mcg,2,20
Allergic_Reaction,Immune_system_disorders,NCT00235989,https://clinicaltrials.gov/show/NCT00235989,Multiple_Sclerosis_Relapsing-Remitting,Interferon_beta_1b_(Betaseron_BAY86-5046)|Interferon_beta_1b_(Betaseron_BAY86-5046)|Interferon_beta_1b_(Betaseron_BAY86-5046)|Interferon_beta_1b_(Betaseron_BAY86-5046)|,6,55,other_events,arm2,ET: IFNB-1b 500 mcg => 500 mcg,3,19
Allergic_Reaction,Immune_system_disorders,NCT00235989,https://clinicaltrials.gov/show/NCT00235989,Multiple_Sclerosis_Relapsing-Remitting,Interferon_beta_1b_(Betaseron_BAY86-5046)|Interferon_beta_1b_(Betaseron_BAY86-5046)|Interferon_beta_1b_(Betaseron_BAY86-5046)|Interferon_beta_1b_(Betaseron_BAY86-5046)|,6,55,other_events,arm0,ET: IFNB-1b 250 mcg => 250 mcg,1,16
allergic_reaction,Injury_poisoning_and_procedural_complications,NCT00238615,https://clinicaltrials.gov/show/NCT00238615,Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Docetaxel|Carboplatin|Radiation_therapy|Surgical_resection|,2,13,serious_events,arm0,Docetaxel / Carboplatin / XRT + Surgical Resection,2,13
ALLERGIC_REACTION,Immune_system_disorders,NCT00252564,https://clinicaltrials.gov/show/NCT00252564,Colorectal_Cancer_Metastatic,Bevacizumab|Oxaliplatin|Leucovorin|Fluorouracil|Cetuximab|,14,357,other_events,arm0,Arm A,9,118
ALLERGIC_REACTION,Immune_system_disorders,NCT00252564,https://clinicaltrials.gov/show/NCT00252564,Colorectal_Cancer_Metastatic,Bevacizumab|Oxaliplatin|Leucovorin|Fluorouracil|Cetuximab|,14,357,other_events,arm1,Arm B,4,121
ALLERGIC_REACTION,Immune_system_disorders,NCT00252564,https://clinicaltrials.gov/show/NCT00252564,Colorectal_Cancer_Metastatic,Bevacizumab|Oxaliplatin|Leucovorin|Fluorouracil|Cetuximab|,14,357,serious_events,arm0,Arm A,1,118
Allergic_reaction,Immune_system_disorders,NCT00253370,https://clinicaltrials.gov/show/NCT00253370,Adenocarcinoma_of_the_Gastroesophageal_Junction|Metastatic_Gastric_Cancer|Advanced_Unresectable_Gastric_Cancer|,BAY_43-9006|docetaxel|cisplatin|,1,44,serious_events,arm0,BAY 43-9006 Docetaxel Cisplatin,1,44
ALLERGIC_REACTION,Immune_system_disorders,NCT00259610,https://clinicaltrials.gov/show/NCT00259610,Rheumatoid_Arthritis,methotrexate|sulfasalazine|hydroxychloroquine|etanercept|,20,755,other_events,arm2,MTX + Placebo Entaneracept,6,255
ALLERGIC_REACTION,Immune_system_disorders,NCT00259610,https://clinicaltrials.gov/show/NCT00259610,Rheumatoid_Arthritis,methotrexate|sulfasalazine|hydroxychloroquine|etanercept|,20,755,other_events,arm1,MTX+ Active SSZ +HCQ,2,132
ALLERGIC_REACTION,Immune_system_disorders,NCT00259610,https://clinicaltrials.gov/show/NCT00259610,Rheumatoid_Arthritis,methotrexate|sulfasalazine|hydroxychloroquine|etanercept|,20,755,other_events,arm3,MTX + Placebo SSZ + HCQ(ST),2,124
ALLERGIC_REACTION,Immune_system_disorders,NCT00259610,https://clinicaltrials.gov/show/NCT00259610,Rheumatoid_Arthritis,methotrexate|sulfasalazine|hydroxychloroquine|etanercept|,20,755,other_events,arm0,MTX + Active Etanercept,10,244
Allergic_Reaction,Immune_system_disorders,NCT00288067,https://clinicaltrials.gov/show/NCT00288067,Adult_Nodular_Lymphocyte_Predominant_Hodgkin_Lymphoma|B-cell_Chronic_Lymphocytic_Leukemia|Contiguous_Stage_II_Adult_Burkitt_Lymphoma|Contiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Contiguous_Stage_II_Adult_Lymphoblastic_Lymphoma|Contiguous_Stage_II_Grade_1_Follicular_Lymphoma|Contiguous_Stage_II_Grade_2_Follicular_Lymphoma|Contiguous_Stage_II_Mantle_Cell_Lymphoma|Stage_II_Marginal_Zone_Lymphoma|Stage_II_Small_Lymphocytic_Lymphoma|Extranodal_Marginal_Zone_B-cell_Lymphoma|Nodal_Marginal_Zone_B-cell_Lymphoma|Noncontiguous_Stage_II_Adult_Burkitt_Lymphoma|Noncontiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Noncontiguous_Stage_II_Adult_Lymphoblastic_Lymphoma|Noncontiguous_Stage_II_Grade_1_Follicular_Lymphoma|Noncontiguous_Stage_II_Grade_2_Follicular_Lymphoma|Noncontiguous_Stage_II_Mantle_Cell_Lymphoma|Recurrent_Adult_Burkitt_Lymphoma|Recurrent_Adult_Diffuse_Large_Cell_Lymphoma|Recurrent_Adult_Hodgkin_Lymphoma|Recurrent_Adult_Lymphoblastic_Lymphoma|Recurrent_Grade_1_Follicular_Lymphoma|Recurrent_Grade_2_Follicular_Lymphoma|Recurrent_Mantle_Cell_Lymphoma|Recurrent_Marginal_Zone_Lymphoma|Recurrent_Small_Lymphocytic_Lymphoma|Refractory_Chronic_Lymphocytic_Leukemia|Splenic_Marginal_Zone_Lymphoma|Stage_I_Adult_Burkitt_Lymphoma|Stage_I_Adult_Diffuse_Large_Cell_Lymphoma|Stage_I_Adult_Hodgkin_Lymphoma|Stage_I_Adult_Lymphoblastic_Lymphoma|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_I_Grade_1_Follicular_Lymphoma|Stage_I_Grade_2_Follicular_Lymphoma|Stage_I_Small_Lymphocytic_Lymphoma|Stage_II_Adult_Hodgkin_Lymphoma|Stage_II_Chronic_Lymphocytic_Leukemia|Stage_III_Adult_Burkitt_Lymphoma|Stage_III_Adult_Diffuse_Large_Cell_Lymphoma|Stage_III_Adult_Hodgkin_Lymphoma|Stage_III_Adult_Lymphoblastic_Lymphoma|Stage_III_Chronic_Lymphocytic_Leukemia|Stage_III_Grade_1_Follicular_Lymphoma|Stage_III_Grade_2_Follicular_Lymphoma|Stage_III_Mantle_Cell_Lymphoma|Stage_III_Marginal_Zone_Lymphoma|Stage_III_Small_Lymphocytic_Lymphoma|Stage_IV_Adult_Burkitt_Lymphoma|Stage_IV_Adult_Diffuse_Large_Cell_Lymphoma|Stage_IV_Adult_Hodgkin_Lymphoma|Stage_IV_Adult_Lymphoblastic_Lymphoma|Stage_IV_Chronic_Lymphocytic_Leukemia|Stage_IV_Grade_1_Follicular_Lymphoma|Stage_IV_Grade_2_Follicular_Lymphoma|Stage_IV_Mantle_Cell_Lymphoma|Stage_IV_Marginal_Zone_Lymphoma|Stage_IV_Small_Lymphocytic_Lymphoma|WaldenstrÕ_m_Macroglobulinemia|,fenretinide|rituximab|,4,64,serious_events,arm0,Fenretinide and Rituximab,1,32
Allergic_Reaction,Immune_system_disorders,NCT00288067,https://clinicaltrials.gov/show/NCT00288067,Adult_Nodular_Lymphocyte_Predominant_Hodgkin_Lymphoma|B-cell_Chronic_Lymphocytic_Leukemia|Contiguous_Stage_II_Adult_Burkitt_Lymphoma|Contiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Contiguous_Stage_II_Adult_Lymphoblastic_Lymphoma|Contiguous_Stage_II_Grade_1_Follicular_Lymphoma|Contiguous_Stage_II_Grade_2_Follicular_Lymphoma|Contiguous_Stage_II_Mantle_Cell_Lymphoma|Stage_II_Marginal_Zone_Lymphoma|Stage_II_Small_Lymphocytic_Lymphoma|Extranodal_Marginal_Zone_B-cell_Lymphoma|Nodal_Marginal_Zone_B-cell_Lymphoma|Noncontiguous_Stage_II_Adult_Burkitt_Lymphoma|Noncontiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Noncontiguous_Stage_II_Adult_Lymphoblastic_Lymphoma|Noncontiguous_Stage_II_Grade_1_Follicular_Lymphoma|Noncontiguous_Stage_II_Grade_2_Follicular_Lymphoma|Noncontiguous_Stage_II_Mantle_Cell_Lymphoma|Recurrent_Adult_Burkitt_Lymphoma|Recurrent_Adult_Diffuse_Large_Cell_Lymphoma|Recurrent_Adult_Hodgkin_Lymphoma|Recurrent_Adult_Lymphoblastic_Lymphoma|Recurrent_Grade_1_Follicular_Lymphoma|Recurrent_Grade_2_Follicular_Lymphoma|Recurrent_Mantle_Cell_Lymphoma|Recurrent_Marginal_Zone_Lymphoma|Recurrent_Small_Lymphocytic_Lymphoma|Refractory_Chronic_Lymphocytic_Leukemia|Splenic_Marginal_Zone_Lymphoma|Stage_I_Adult_Burkitt_Lymphoma|Stage_I_Adult_Diffuse_Large_Cell_Lymphoma|Stage_I_Adult_Hodgkin_Lymphoma|Stage_I_Adult_Lymphoblastic_Lymphoma|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_I_Grade_1_Follicular_Lymphoma|Stage_I_Grade_2_Follicular_Lymphoma|Stage_I_Small_Lymphocytic_Lymphoma|Stage_II_Adult_Hodgkin_Lymphoma|Stage_II_Chronic_Lymphocytic_Leukemia|Stage_III_Adult_Burkitt_Lymphoma|Stage_III_Adult_Diffuse_Large_Cell_Lymphoma|Stage_III_Adult_Hodgkin_Lymphoma|Stage_III_Adult_Lymphoblastic_Lymphoma|Stage_III_Chronic_Lymphocytic_Leukemia|Stage_III_Grade_1_Follicular_Lymphoma|Stage_III_Grade_2_Follicular_Lymphoma|Stage_III_Mantle_Cell_Lymphoma|Stage_III_Marginal_Zone_Lymphoma|Stage_III_Small_Lymphocytic_Lymphoma|Stage_IV_Adult_Burkitt_Lymphoma|Stage_IV_Adult_Diffuse_Large_Cell_Lymphoma|Stage_IV_Adult_Hodgkin_Lymphoma|Stage_IV_Adult_Lymphoblastic_Lymphoma|Stage_IV_Chronic_Lymphocytic_Leukemia|Stage_IV_Grade_1_Follicular_Lymphoma|Stage_IV_Grade_2_Follicular_Lymphoma|Stage_IV_Mantle_Cell_Lymphoma|Stage_IV_Marginal_Zone_Lymphoma|Stage_IV_Small_Lymphocytic_Lymphoma|WaldenstrÕ_m_Macroglobulinemia|,fenretinide|rituximab|,4,64,other_events,arm0,Fenretinide and Rituximab,3,32
Allergic_reaction,Immune_system_disorders,NCT00293462,https://clinicaltrials.gov/show/NCT00293462,Head_and_Neck_Cancer|Mucositis|Radiation_Toxicity|,sargramostim|oral_salt_and_soda_mouthwash|,1,28,serious_events,arm1,Arm II: Salt & Soda Group (SS),1,28
Allergic_Reaction,General_disorders,NCT00297596,https://clinicaltrials.gov/show/NCT00297596,Breast_Cancer,Trastuzumab|Oxaliplatin|,3,50,serious_events,arm0,Oxaliplatin/Trastuzumab,1,25
Allergic_Reaction,General_disorders,NCT00297596,https://clinicaltrials.gov/show/NCT00297596,Breast_Cancer,Trastuzumab|Oxaliplatin|,3,50,other_events,arm0,Oxaliplatin/Trastuzumab,2,25
Allergic_reaction,Investigations,NCT00301028,https://clinicaltrials.gov/show/NCT00301028,Head_and_Neck_Cancer,Cetuximab|Carboplatin|Paclitaxel|Conventional_Surgery|Radiation_Therapy|,2,47,serious_events,arm0,Cetuximab + Carboplatin/Paclitaxel,2,47
Allergic_reaction,Immune_system_disorders,NCT00300885,https://clinicaltrials.gov/show/NCT00300885,Carcinoma_Non-Small_Cell_Lung,Nexavar_(Sorafenib_BAY43-9006)_+_carboplatin_+_paclitaxel|Carboplatin_plus_Paclitaxel|,74,1844,other_events,arm1,Placebo + C/P,30,459
Allergic_reaction,Immune_system_disorders,NCT00300885,https://clinicaltrials.gov/show/NCT00300885,Carcinoma_Non-Small_Cell_Lung,Nexavar_(Sorafenib_BAY43-9006)_+_carboplatin_+_paclitaxel|Carboplatin_plus_Paclitaxel|,74,1844,other_events,arm0,Sorafenib + C/P,29,463
Allergic_reaction,Immune_system_disorders,NCT00300885,https://clinicaltrials.gov/show/NCT00300885,Carcinoma_Non-Small_Cell_Lung,Nexavar_(Sorafenib_BAY43-9006)_+_carboplatin_+_paclitaxel|Carboplatin_plus_Paclitaxel|,74,1844,serious_events,arm1,Placebo + C/P,4,459
Allergic_reaction,Immune_system_disorders,NCT00300885,https://clinicaltrials.gov/show/NCT00300885,Carcinoma_Non-Small_Cell_Lung,Nexavar_(Sorafenib_BAY43-9006)_+_carboplatin_+_paclitaxel|Carboplatin_plus_Paclitaxel|,74,1844,serious_events,arm0,Sorafenib + C/P,11,463
Allergic_reaction,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,20,184,serious_events,arm3,Phase II: MGd 5 mg/kg,4,81
Allergic_reaction,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,20,184,other_events,arm2,Phase I: MGd 5 mg/kg,3,6
Allergic_reaction,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,20,184,other_events,arm3,Phase II: MGd 5 mg/kg,11,81
Allergic_reaction,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,20,184,serious_events,arm1,Phase I: MGd 4 mg/kg,1,9
Allergic_reaction,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,20,184,other_events,arm0,Phase I: MGd 3 mg/kg,1,7
Allergic_reaction,Immune_system_disorders,NCT00305877,https://clinicaltrials.gov/show/NCT00305877,Stage_IA_Pancreatic_Cancer|Stage_IB_Pancreatic_Cancer|Stage_IIA_Pancreatic_Cancer|Stage_IIB_Pancreatic_Cancer|,cetuximab|gemcitabine_hydrochloride|capecitabine|radiation_therapy|bevacizumab|laboratory_biomarker_analysis|,1,67,serious_events,arm0,Arm A (Cetuximab Gemcitabine Capecitabine Radiation),1,67
Allergic_reaction,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,374,6538,other_events,arm1,Docetaxel + Doxorubicin and Cyclophosphamide (TAC),190,1635
Allergic_reaction,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,374,6538,serious_events,arm1,Docetaxel + Doxorubicin and Cyclophosphamide (TAC),5,1635
Allergic_reaction,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,374,6538,serious_events,arm0,Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T),7,1634
Allergic_reaction,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,374,6538,other_events,arm0,Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T),172,1634
Allergic_reaction,Immune_system_disorders,NCT00321646,https://clinicaltrials.gov/show/NCT00321646,Prostate_Cancer|Adenocarcinoma_of_the_Prostate|,Bevacizumab|Docetaxel|,6,82,serious_events,arm0,Chemotherapy,1,41
Allergic_reaction,Immune_system_disorders,NCT00321646,https://clinicaltrials.gov/show/NCT00321646,Prostate_Cancer|Adenocarcinoma_of_the_Prostate|,Bevacizumab|Docetaxel|,6,82,other_events,arm0,Chemotherapy,5,41
Allergic_reaction,Immune_system_disorders,NCT00321685,https://clinicaltrials.gov/show/NCT00321685,Adenocarcinoma_of_the_Rectum|Stage_II_Rectal_Cancer|Stage_III_Rectal_Cancer|,radiation_therapy|capecitabine|oxaliplatin|bevacizumab|surgery|leucovorin_calcium|fluorouracil|,1,55,serious_events,arm0,Arm I,1,55
Allergic_Reaction,Immune_system_disorders,NCT00321893,https://clinicaltrials.gov/show/NCT00321893,Lung_Cancer,Budesonide|Placebo|,1,98,other_events,arm0,Arm I: Budesonide,1,98
Allergic_reaction,Immune_system_disorders,NCT00326495,https://clinicaltrials.gov/show/NCT00326495,Metastatic_Colorectal_Cancer,Cetuximab|BAY_43-9006|,1,50,other_events,arm0,BAY 43-9006 & Cetuximab,1,50
Allergic_Reaction,Immune_system_disorders,NCT00338988,https://clinicaltrials.gov/show/NCT00338988,Cancer_of_the_Gallbladder|Cancer_of_the_Biliary_Tract|,Capecitabine|Oxaliplatin|,1,18,serious_events,arm0,Stratum: 1 Prior Regimen,1,18
Allergic_reaction,Immune_system_disorders,NCT00343512,https://clinicaltrials.gov/show/NCT00343512,Breast_Cancer,docetaxel|protein_expression_analysis|laboratory_biomarker_analysis|biopsy|conventional_surgery|neoadjuvant_therapy|,2,32,other_events,arm0,Therapeutic Intervention,2,32
Allergic_reaction,Immune_system_disorders,NCT00357500,https://clinicaltrials.gov/show/NCT00357500,Central_Nervous_System_Tumor_Pediatric|Leukemia|Lymphoma|Neuroblastoma|Sarcoma|Unspecified_Childhood_Solid_Tumor_Protocol_Specific|,celecoxib|cyclophosphamide|etoposide|fenofibrate|thalidomide|,1,97,other_events,arm0,5-drug Metronomic Antiangiogenic Regimen,1,97
Allergic_reaction,General_disorders,NCT00366249,https://clinicaltrials.gov/show/NCT00366249,Bacterial_Infections|Diabetic_Foot|Osteomyelitis|,Tigecycline|Ertapenem|,1,553,serious_events,arm0,Tigecycline,1,553
Allergic_reaction,Immune_system_disorders,NCT00369122,https://clinicaltrials.gov/show/NCT00369122,Cervical_Adenocarcinoma|Cervical_Adenosquamous_Cell_Carcinoma|Cervical_Squamous_Cell_Carcinoma|Stage_IB_Cervical_Cancer|Stage_IIA_Cervical_Cancer|Stage_IIB_Cervical_Cancer|Stage_III_Cervical_Cancer|,external_beam_radiation_therapy|brachytherapy|bevacizumab|cisplatin|,1,59,serious_events,arm0,Treatment (Radiation Therapy Bevacizumab Cisplatin),1,59
Allergic_reaction,General_disorders,NCT00369343,https://clinicaltrials.gov/show/NCT00369343,Depression|Depressive_Disorder|Depressive_Disorder_Major|,Desvenlafaxine_administered_as_a_succinate_salt_in_a_sustained-release_form_(DVS_SR)|Placebo|,1,208,serious_events,arm2,Open-label DVS SR/ DVS SR,1,208
Allergic_reaction,Immune_system_disorders,NCT00372619,https://clinicaltrials.gov/show/NCT00372619,Leukemia,clofarabine|cytarabine|methotrexate|laboratory_biomarker_analysis|,2,40,other_events,arm5,Clofarabine 52 mg/më_ to Assess Efficacy in AML Patients,2,40
Allergic_reaction,Immune_system_disorders,NCT00372593,https://clinicaltrials.gov/show/NCT00372593,Leukemia,asparaginase|cytarabine|daunorubicin_hydrochloride|etoposide|gemtuzumab_ozogamicin|mitoxantrone_hydrochloride|,1,6,other_events,arm2,Arm A: Standard Arm - No GMTZ AML Patients With Down Syndrome,1,6
Allergic_reaction,Immune_system_disorders,NCT00378703,https://clinicaltrials.gov/show/NCT00378703,Clear_Cell_Renal_Cell_Carcinoma|Recurrent_Renal_Cell_Cancer|Stage_IV_Renal_Cell_Cancer|,Sorafenib|temsirolimus|bevacizumab|,10,268,other_events,arm1,Arm B (Bevacizumab and Temsirolimus),5,86
Allergic_reaction,Immune_system_disorders,NCT00378703,https://clinicaltrials.gov/show/NCT00378703,Clear_Cell_Renal_Cell_Carcinoma|Recurrent_Renal_Cell_Cancer|Stage_IV_Renal_Cell_Cancer|,Sorafenib|temsirolimus|bevacizumab|,10,268,serious_events,arm3,Arm D (Sorafenib and Temsirolimus),1,91
Allergic_reaction,Immune_system_disorders,NCT00378703,https://clinicaltrials.gov/show/NCT00378703,Clear_Cell_Renal_Cell_Carcinoma|Recurrent_Renal_Cell_Cancer|Stage_IV_Renal_Cell_Cancer|,Sorafenib|temsirolimus|bevacizumab|,10,268,other_events,arm3,Arm D (Sorafenib and Temsirolimus),4,91
Allergic_reaction,General_disorders,NCT00381550,https://clinicaltrials.gov/show/NCT00381550,Accelerated_Phase_Chronic_Myelogenous_Leukemia|Atypical_Chronic_Myeloid_Leukemia_BCR-ABL1_Negative|Blastic_Phase_Chronic_Myelogenous_Leukemia|Chronic_Eosinophilic_Leukemia|Chronic_Myelomonocytic_Leukemia|Essential_Thrombocythemia|Philadelphia_Chromosome_Negative_Chronic_Myelogenous_Leukemia|Polycythemia_Vera|Primary_Myelofibrosis|Relapsing_Chronic_Myelogenous_Leukemia|,fludarabine_phosphate|triapine|laboratory_biomarker_analysis|,5,35,other_events,arm0,Arm I,5,35
Allergic_reaction,Immune_system_disorders,NCT00387790,https://clinicaltrials.gov/show/NCT00387790,Untreated_Childhood_Brain_Stem_Glioma,motexafin_gadolinium|3-dimensional_conformal_radiation_therapy|,1,62,other_events,arm0,Radiation and Motexafin Gadolinium,1,62
Allergic_reaction,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,12,128,other_events,arm0,Paclitaxel/Carboplatin/Sorafenib,7,43
Allergic_reaction,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,12,128,serious_events,arm1,Paclitaxel/Carboplatin,1,42
Allergic_reaction,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,12,128,serious_events,arm0,Paclitaxel/Carboplatin/Sorafenib,4,43
Allergic_Reaction,Immune_system_disorders,NCT00392392,https://clinicaltrials.gov/show/NCT00392392,Breast_Cancer,nab-paclitaxel|Bevacizumab|Trastuzumab|,2,29,other_events,arm0,Nab-Paclitaxel/Bevacizumab/Trastuzumab,2,29
Allergic_reaction,Skin_and_subcutaneous_tissue_disorders,NCT00395226,https://clinicaltrials.gov/show/NCT00395226,Rosacea,zinc_sulfate|placebo|,1,27,serious_events,arm1,Zinc Sulfate,1,27
Allergic_reaction,General_disorders,NCT00402740,https://clinicaltrials.gov/show/NCT00402740,Carotid_Artery_Disease,Xact_Stent_with_either_Emboshield_Pro_(Gen_5)_or_Emboshield_(Gen_3),1,313,serious_events,arm0,Group 1,1,313
Allergic_reaction,Immune_system_disorders,NCT00408694,https://clinicaltrials.gov/show/NCT00408694,Stage_II_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_III_Lymphoepithelioma_of_the_Nasopharynx|Stage_III_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_IV_Lymphoepithelioma_of_the_Nasopharynx|Stage_IV_Squamous_Cell_Carcinoma_of_the_Nasopharynx|,3-dimensional_conformal_radiation_therapy|intensity-modulated_radiation_therapy|bevacizumab|cisplatin|fluorouracil|,1,44,other_events,arm0,Treatment (Bevacizumab Cisplatin Fluorouracil IMRT 3D-CRT),1,44
Allergic_reaction,Immune_system_disorders,NCT00410904,https://clinicaltrials.gov/show/NCT00410904,Recurrent_Non-small_Cell_Lung_Cancer,cediranib_maleate|pemetrexed_disodium|,1,40,serious_events,arm0,Arm I - Cohort A,1,40
Allergic_reaction,Immune_system_disorders,NCT00416494,https://clinicaltrials.gov/show/NCT00416494,Colorectal_Cancer,bevacizumab|oxaliplatin|Capecitabine|Capecitabine|,1,19,other_events,arm0,Initial Cohort,1,19
Allergic_reaction,Immune_system_disorders,NCT00423293,https://clinicaltrials.gov/show/NCT00423293,Anal_Cancer,fluorouracil|mitomycin_C|Intensity-modulated_radiation_therapy|,2,52,other_events,arm0,5-FU + Mitomycin + IMRT,2,52
Allergic_reaction,Immune_system_disorders,NCT00433381,https://clinicaltrials.gov/show/NCT00433381,Adult_Glioblastoma|Adult_Gliosarcoma|Recurrent_Adult_Brain_Tumor|,irinotecan_hydrochloride|bevacizumab|temozolomide|,2,117,other_events,arm0,Arm I (Bevacizumab and Temozolomide),1,60
Allergic_reaction,Immune_system_disorders,NCT00433381,https://clinicaltrials.gov/show/NCT00433381,Adult_Glioblastoma|Adult_Gliosarcoma|Recurrent_Adult_Brain_Tumor|,irinotecan_hydrochloride|bevacizumab|temozolomide|,2,117,other_events,arm1,Arm II (Bevacizumab and Irinotecan Hydrochloride),1,57
Allergic_reaction,Immune_system_disorders,NCT00433537,https://clinicaltrials.gov/show/NCT00433537,Contiguous_Stage_II_Mantle_Cell_Lymphoma|Noncontiguous_Stage_II_Mantle_Cell_Lymphoma|Stage_I_Mantle_Cell_Lymphoma|Stage_III_Mantle_Cell_Lymphoma|Stage_IV_Mantle_Cell_Lymphoma|,bortezomib|rituximab|cyclophosphamide|doxorubicin_hydrochloride|vincristine|dexamethasone|filgrastim|pegfilgrastim|Autologous_stem_cell_transplantation_(ASCT)|,1,77,serious_events,arm0,Step 1 - VcR-CVAD Induction,1,77
Allergic_reaction,Immune_system_disorders,NCT00436215,https://clinicaltrials.gov/show/NCT00436215,Ovarian_Neoplasm|Fallopian_Tube_Cancer|Primary_Peritoneal_Cancer|,Bevacizumab|BAY_43-9006|,3,110,serious_events,arm0,BAY 43-9006 + Bevacizumab,1,55
Allergic_reaction,Immune_system_disorders,NCT00436215,https://clinicaltrials.gov/show/NCT00436215,Ovarian_Neoplasm|Fallopian_Tube_Cancer|Primary_Peritoneal_Cancer|,Bevacizumab|BAY_43-9006|,3,110,other_events,arm0,BAY 43-9006 + Bevacizumab,2,55
ALLERGIC_REACTION,Immune_system_disorders,NCT00438399,https://clinicaltrials.gov/show/NCT00438399,Scalp_Psoriasis,C._propionate_-_Corticosteroid_1|C._propionate-_Corticosteroid_2|C._propionate_-Corticosteroid_3|Corticosteroid_1-_C._propionate|Corticosteroid_2_-_C._propionate|Corticosteroid_3_-_C._propionate|,1,67,serious_events,arm1,Corticosteroid 2,1,67
Allergic_reaction,Immune_system_disorders,NCT00447330,https://clinicaltrials.gov/show/NCT00447330,Esophageal_Neoplasms|Stomach_Neoplasms|Neoplasm_Metastasis|,capecitabine_(Xeloda)_oxaliplatin_and_bevacizumab_(Avastin),1,58,other_events,arm0,1 - Capecitabine (Xeloda) Oxaliplatin and Bevacizumab (Avasti,1,58
Allergic_reaction,Immune_system_disorders,NCT00449033,https://clinicaltrials.gov/show/NCT00449033,Carcinoma_Non-Small-Cell_Lung,Sorafenib_(Nexavar_BAY43-9006)|Placebo|Gemcitabine|Cisplatin|,1,452,serious_events,arm0,Sorafenib (Nexavar BAY43-9006) + GC,1,452
Allergic_Reaction,Injury_poisoning_and_procedural_complications,NCT00450372,https://clinicaltrials.gov/show/NCT00450372,Melanoma_(Skin),ADI-PEG-20|Pharmacology_Studies|,1,37,serious_events,arm0,Single Arm,1,37
Allergic_reaction,Immune_system_disorders,NCT00450619,https://clinicaltrials.gov/show/NCT00450619,Prostate_Cancer,Samarium_Sm_153_lexidronam_pentasodium|Sargramostim|Recombinant_vaccinia-TRICOM_vaccine|Recombinant_fowlpox-TRICOM_vaccine|,1,22,other_events,arm1,Arm B - 153SmEDTMP With Vaccine,1,22
Allergic_reaction,Immune_system_disorders,NCT00455975,https://clinicaltrials.gov/show/NCT00455975,Renal_Cancer|Kidney_Cancer|,Bevacizumab,13,119,other_events,arm1,Bi-weekly Avastin,9,61
Allergic_reaction,Immune_system_disorders,NCT00455975,https://clinicaltrials.gov/show/NCT00455975,Renal_Cancer|Kidney_Cancer|,Bevacizumab,13,119,other_events,arm0,Weekly Avastin,4,58
Allergic_reaction,Immune_system_disorders,NCT00461708,https://clinicaltrials.gov/show/NCT00461708,Pancreatic_Cancer,Erlotinib|Gemcitabine|,1,115,other_events,arm0,Erlotinib Gemcitabine: Rash Grade < 2,1,115
allergic_reaction,General_disorders,NCT00466505,https://clinicaltrials.gov/show/NCT00466505,Colorectal_Cancer,cetuximab|celecoxib|proteomic_profiling|immunohistochemistry_staining_method|laboratory_biomarker_analysis|mass_spectrometry|,3,17,other_events,arm0,Therapeutic Intervention,3,17
Allergic_Reaction,Immune_system_disorders,NCT00475085,https://clinicaltrials.gov/show/NCT00475085,Nausea,aprepitant|dexamethasone|granisetron_hydrochloride|palonosetron_hydrochloride|prochlorperazine|placebo|,3,514,serious_events,arm2,Arm I,1,254
Allergic_Reaction,Immune_system_disorders,NCT00475085,https://clinicaltrials.gov/show/NCT00475085,Nausea,aprepitant|dexamethasone|granisetron_hydrochloride|palonosetron_hydrochloride|prochlorperazine|placebo|,3,514,serious_events,arm1,Arm III,2,260
Allergic_reaction,Immune_system_disorders,NCT00479674,https://clinicaltrials.gov/show/NCT00479674,Breast_Cancer,Abraxane|Bevacizumab|Carboplatin|,4,82,serious_events,arm0,Abraxane Carboplatin Bevacizumab,1,41
Allergic_reaction,Immune_system_disorders,NCT00479674,https://clinicaltrials.gov/show/NCT00479674,Breast_Cancer,Abraxane|Bevacizumab|Carboplatin|,4,82,other_events,arm0,Abraxane Carboplatin Bevacizumab,3,41
Allergic_reaction,General_disorders,NCT00492284,https://clinicaltrials.gov/show/NCT00492284,Choroidal_Neovascularization|Macular_Degeneration|,verteporfin|verteporfin|ranibizumab|dexamethasone|,8,162,other_events,arm1,1/2 Fluence Triple Therapy,2,39
Allergic_reaction,General_disorders,NCT00492284,https://clinicaltrials.gov/show/NCT00492284,Choroidal_Neovascularization|Macular_Degeneration|,verteporfin|verteporfin|ranibizumab|dexamethasone|,8,162,other_events,arm0,1/4 Fluence Triple Therapy,2,39
Allergic_reaction,General_disorders,NCT00492284,https://clinicaltrials.gov/show/NCT00492284,Choroidal_Neovascularization|Macular_Degeneration|,verteporfin|verteporfin|ranibizumab|dexamethasone|,8,162,other_events,arm2,1/2 Fluence Double Therapy,1,43
Allergic_reaction,General_disorders,NCT00492284,https://clinicaltrials.gov/show/NCT00492284,Choroidal_Neovascularization|Macular_Degeneration|,verteporfin|verteporfin|ranibizumab|dexamethasone|,8,162,other_events,arm3,Ranibizumab,3,41
Allergic_Reaction,Immune_system_disorders,NCT00492752,https://clinicaltrials.gov/show/NCT00492752,Carcinoma_Hepatocellular,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,6,224,other_events,arm1,Placebo All (Double-Blind and Open Label Phase),4,75
Allergic_Reaction,Immune_system_disorders,NCT00492752,https://clinicaltrials.gov/show/NCT00492752,Carcinoma_Hepatocellular,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,6,224,other_events,arm0,Sorafenib All (Double-Blind and Open Label Phase),2,149
Allergic_reaction,General_disorders,NCT00496626,https://clinicaltrials.gov/show/NCT00496626,Papillomavirus_Infections,Quadrivalent_Human_Papillomavirus_(HPV_Types_6_11_16_18)_Recombinant_Vaccine_(Gardasilëå)|Comparator:_Placebo|,10,600,other_events,arm1,Placebo Group,2,298
Allergic_reaction,General_disorders,NCT00496626,https://clinicaltrials.gov/show/NCT00496626,Papillomavirus_Infections,Quadrivalent_Human_Papillomavirus_(HPV_Types_6_11_16_18)_Recombinant_Vaccine_(Gardasilëå)|Comparator:_Placebo|,10,600,other_events,arm0,Vaccine (Gardasilëå) Group,8,302
Allergic_Reaction,Immune_system_disorders,NCT00499694,https://clinicaltrials.gov/show/NCT00499694,Prostate_Cancer,bevacizumab|satraplatin|,3,60,serious_events,arm0,Bevacizumab and Satraplatin,1,30
Allergic_Reaction,Immune_system_disorders,NCT00499694,https://clinicaltrials.gov/show/NCT00499694,Prostate_Cancer,bevacizumab|satraplatin|,3,60,other_events,arm0,Bevacizumab and Satraplatin,2,30
Allergic_Reaction,General_disorders,NCT00502203,https://clinicaltrials.gov/show/NCT00502203,Mixed_Tumor_Mullerian,Carboplatin|Paclitaxel|,2,23,other_events,arm0,Paclitaxel + Carboplatin,2,23
Allergic_Reaction,Immune_system_disorders,NCT00506597,https://clinicaltrials.gov/show/NCT00506597,Leukemia,Erwinase,1,33,other_events,arm0,Erwinase,1,33
Allergic_reaction,Immune_system_disorders,NCT00509366,https://clinicaltrials.gov/show/NCT00509366,Non_Small_Cell_Lung_Cancer,Cisplatin_&_Gemcitabine|Cisplatin_&_Pemetrexed|Docetaxel_&_Gemcitabine|Pemetrexed_&_Gemcitabine|,2,33,other_events,arm2,Cisplatin Resistant (Pre-Amendment),1,17
Allergic_reaction,Immune_system_disorders,NCT00509366,https://clinicaltrials.gov/show/NCT00509366,Non_Small_Cell_Lung_Cancer,Cisplatin_&_Gemcitabine|Cisplatin_&_Pemetrexed|Docetaxel_&_Gemcitabine|Pemetrexed_&_Gemcitabine|,2,33,serious_events,arm0,Cisplatin Sensitive (Pre-Amendment),1,16
allergic_reaction,Immune_system_disorders,NCT00512096,https://clinicaltrials.gov/show/NCT00512096,Penile_Cancer,Ifosfamide|Paclitaxel_(Taxol)|Cisplatin|,1,23,serious_events,arm0,Cisplatin + Ifosfamide + Paclitaxel,1,23
Allergic_reaction,Immune_system_disorders,NCT00513604,https://clinicaltrials.gov/show/NCT00513604,Melanoma|Malignant_Melanoma|Melanoma_Experimental|Experimental_Melanomas|,aldesleukin|therapeutic_autologous_lymphocytes|Cyclophosphamide|Fludarabine_phosphate|Total_body_irradiation|,1,26,other_events,arm0,Cohort 1 - NMA TIL Aldesleukin,1,26
Allergic_reaction,Immune_system_disorders,NCT00516295,https://clinicaltrials.gov/show/NCT00516295,Ewing_Sarcoma_of_Bone|Extraosseous_Ewing_Sarcoma|Peripheral_Primitive_Neuroectodermal_Tumor|Recurrent_Ewing_Sarcoma/Peripheral_Primitive_Neuroectodermal_Tumor|,topotecan_hydrochloride|vincristine_sulfate|cyclophosphamide|bevacizumab|,1,6,other_events,arm0,Arm I (Feasibility Assessment of VTCB),1,6
Allergic_Reaction,Skin_and_subcutaneous_tissue_disorders,NCT00525876,https://clinicaltrials.gov/show/NCT00525876,Lymphoma,Cyclophosphamide|Fludarabine|Rituximab|Alemtuzumab|Allogeneic_Stem_Cell_Infusion|,1,16,serious_events,arm0,Matched Sibling Transplant,1,16
Allergic_reaction,Immune_system_disorders,NCT00537030,https://clinicaltrials.gov/show/NCT00537030,Adult_Acute_Lymphoblastic_Leukemia|Childhood_Acute_Lymphoblastic_Leukemia|,laboratory_biomarker_analysis|pharmacological_study|asparaginase|,3,55,other_events,arm0,Erwinia Asparaginase,3,55
Allergic_Reaction,Immune_system_disorders,NCT00541099,https://clinicaltrials.gov/show/NCT00541099,Lung_Cancer,bevacizumab|docetaxel|,1,8,other_events,arm0,Avastin & Docetaxel,1,8
Allergic_reaction,Immune_system_disorders,NCT00545948,https://clinicaltrials.gov/show/NCT00545948,Carcinoma_Non-Small-Cell_Lung,Vinorelbine_followed_by_Cisplatin|Pemetrexed_followed_by_Cisplatin|,1,8,other_events,arm0,Arm A-Vinorelbine,1,8
Allergic_Reaction,Immune_system_disorders,NCT00546156,https://clinicaltrials.gov/show/NCT00546156,Breast_Cancer,Doxorubicin|Cyclophosphamide|Paclitaxel|Bevacizumab|,10,104,other_events,arm0,All Study Participants,10,104
Allergic_reaction,Infections_and_infestations,NCT00547534,https://clinicaltrials.gov/show/NCT00547534,Non-Hodgkin's_Lymphoma,bortezomib|bendamustine|rituximab|,4,30,other_events,arm0,Lymphoma Subjects,4,30
Allergic_reaction,Immune_system_disorders,NCT00551759,https://clinicaltrials.gov/show/NCT00551759,Esophageal_Cancer,5-Fluorouracil|Oxaliplatin|Cetuximab|Docetaxel|Surgery|Radiotherapy|,1,22,serious_events,arm0,Neoadjuvant Therapy Surgery Adjuvant Therapy,1,22
Allergic_reaction,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,9,135,serious_events,arm1,Placebo + Paclitaxel + Carboplatin,1,44
Allergic_reaction,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,9,135,other_events,arm1,Placebo + Paclitaxel + Carboplatin,2,44
Allergic_reaction,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,9,135,other_events,arm0,Sorafenib + Paclitaxel + Carboplatin,6,47
Allergic_reaction,Immune_system_disorders,NCT00586495,https://clinicaltrials.gov/show/NCT00586495,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006),6,95,other_events,arm0,Sorafenib (Nexavar BAY43-9006),6,95
Allergic_reaction,Immune_system_disorders,NCT00588809,https://clinicaltrials.gov/show/NCT00588809,Adult_Acute_Myeloid_Leukemia_With_t(15;17)(q22;q12)|Adult_Acute_Promyelocytic_Leukemia_(M3)|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|Recurrent_Adult_Acute_Myeloid_Leukemia|Secondary_Acute_Myeloid_Leukemia|,selumetinib,5,47,other_events,arm0,Selumetinib,5,47
Allergic_reaction,Immune_system_disorders,NCT00589290,https://clinicaltrials.gov/show/NCT00589290,Thymoma|Thymic_Carcinoma|,Belinostat_(PDX101),8,41,other_events,arm0,Belinostat Treatment,8,41
Allergic_Reaction,Immune_system_disorders,NCT00591734,https://clinicaltrials.gov/show/NCT00591734,Metastatic_Melanoma,Bevacizumab|Everolimus|,4,57,other_events,arm0,Intervention,4,57
allergic_reaction,Immune_system_disorders,NCT00593827,https://clinicaltrials.gov/show/NCT00593827,Metastatic_Breast_Cancer,Ixabepilone|Ixabepilone|,11,171,other_events,arm1,Ixabepilone 40 mg/m^2,6,89
allergic_reaction,Immune_system_disorders,NCT00593827,https://clinicaltrials.gov/show/NCT00593827,Metastatic_Breast_Cancer,Ixabepilone|Ixabepilone|,11,171,other_events,arm0,Ixabepilone 16 mg/m^2,5,82
Allergic_reaction,Immune_system_disorders,NCT00613080,https://clinicaltrials.gov/show/NCT00613080,Colorectal_Cancer,capecitabine|oxaliplatin|resection|radiation_therapy|FOLFOX|,5,68,other_events,arm0,IMRT + Chemotherapy  Resection Postoperative Chemotherapy,5,68
Allergic_reaction,Immune_system_disorders,NCT00616967,https://clinicaltrials.gov/show/NCT00616967,Breast_Cancer,carboplatin|paclitaxel_albumin-stabilized_nanoparticle_formulation|vorinostat|placebo|,11,62,other_events,arm2,Arm II,1,31
Allergic_reaction,Immune_system_disorders,NCT00616967,https://clinicaltrials.gov/show/NCT00616967,Breast_Cancer,carboplatin|paclitaxel_albumin-stabilized_nanoparticle_formulation|vorinostat|placebo|,11,62,other_events,arm1,Arm I,10,31
Allergic_reaction,Immune_system_disorders,NCT00618982,https://clinicaltrials.gov/show/NCT00618982,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006),1,83,serious_events,arm0,Sorafenib (Nexavar BAY43-9006),1,83
Allergic_reaction,Immune_system_disorders,NCT00621049,https://clinicaltrials.gov/show/NCT00621049,Non-Small_Cell_Lung_Cancer,Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel/Carboplatin|,6,112,other_events,arm0,Docetaxel/Carboplatin/Bevacizumab/Erlotinib,4,55
Allergic_reaction,Immune_system_disorders,NCT00621049,https://clinicaltrials.gov/show/NCT00621049,Non-Small_Cell_Lung_Cancer,Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel/Carboplatin|,6,112,other_events,arm1,Docetaxel and Carboplatin,2,57
Allergic_reaction,Immune_system_disorders,NCT00626821,https://clinicaltrials.gov/show/NCT00626821,Stoma,SenSura,1,3017,other_events,arm0,SenSura,1,3017
Allergic_reaction,Immune_system_disorders,NCT00627497,https://clinicaltrials.gov/show/NCT00627497,Degenerative_Lumbar_Spinal_Stenosis,Single-Level_Posterior_Decompression|DIAM_Spinal_Stabilization|DIAM_Spinal_Stabilization|Fusion|,1,12,other_events,arm1,Single-Level Posterior Decompression,1,12
Allergic_reaction,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),7,33,other_events,arm5,Non-guided TC,2,7
Allergic_reaction,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),7,33,serious_events,arm5,Non-guided TC,1,7
Allergic_reaction,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),7,33,other_events,arm3,Guided TC Non-Sensitive,1,6
Allergic_reaction,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),7,33,other_events,arm1,Guided TC Sensitive,2,7
Allergic_reaction,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),7,33,other_events,arm2,Guided AC Non-sensitive,1,6
Allergic_reaction,Immune_system_disorders,NCT00637247,https://clinicaltrials.gov/show/NCT00637247,Pancreatic_Neoplasms,imexon_in_combination_with_gemcitabine|imexon_placebo_+_gemcitabine|,1,67,serious_events,arm0,Amplimexon (Imexon) + Gemcitabine,1,67
Allergic_reaction,Immune_system_disorders,NCT00643097,https://clinicaltrials.gov/show/NCT00643097,Malignant_Neoplasms_of_Brain,PEP-3_vaccine|sargramostim|Temozolomide|,1,18,serious_events,arm0,Arm I (ACTIVATE),1,18
Allergic_reaction,Immune_system_disorders,NCT00645333,https://clinicaltrials.gov/show/NCT00645333,Metastatic_Breast_Cancer,MK-0752_Docetaxel_Pegfilgrastim,4,30,other_events,arm0,MK-0752,4,30
Allergic_Reaction,Immune_system_disorders,NCT00654953,https://clinicaltrials.gov/show/NCT00654953,Cocaine_Dependence|Depressive_Symptoms|,sertraline|Placebo|gabapentin|,1,30,serious_events,arm2,Active Group: Sertraline Plus Gabapentin,1,30
Allergic_reaction,Immune_system_disorders,NCT00658697,https://clinicaltrials.gov/show/NCT00658697,Prostate_Cancer,Docetaxel|Bevacizumab|ADT|Bicalutamide|,9,82,other_events,arm0,Docetaxel Bevacizumab and ADT,8,41
Allergic_reaction,Immune_system_disorders,NCT00658697,https://clinicaltrials.gov/show/NCT00658697,Prostate_Cancer,Docetaxel|Bevacizumab|ADT|Bicalutamide|,9,82,serious_events,arm0,Docetaxel Bevacizumab and ADT,1,41
Allergic_reaction,Immune_system_disorders,NCT00660010,https://clinicaltrials.gov/show/NCT00660010,Puberty_Precocious,Lupron_(leuprolide_acetate),6,55,other_events,arm0,Leuprolide Acetate 1 Month Depot,6,55
Allergic_Reaction,Immune_system_disorders,NCT00661453,https://clinicaltrials.gov/show/NCT00661453,Spinal_Muscular_Atrophy_Type_I,Valproic_Acid_and_Levocarnitine,1,38,other_events,arm0,SMA Type 1,1,38
Allergic_Reaction,Immune_system_disorders,NCT00664326,https://clinicaltrials.gov/show/NCT00664326,Carcinoma_Renal_Cell,Regorafenib_(Stivarga_BAY73-4506),4,49,other_events,arm0,Regorafenib (Stivarga BAY73-4506),4,49
Allergic_reaction,Immune_system_disorders,NCT00666588,https://clinicaltrials.gov/show/NCT00666588,Adult_Acute_Monoblastic_Leukemia_(M5a)|Adult_Acute_Monocytic_Leukemia_(M5b)|Adult_Acute_Myeloblastic_Leukemia_With_Maturation_(M2)|Adult_Acute_Myeloblastic_Leukemia_Without_Maturation_(M1)|Adult_Acute_Myeloid_Leukemia_With_11q23_(MLL)_Abnormalities|Adult_Acute_Myeloid_Leukemia_With_Del(5q)|Adult_Acute_Myeloid_Leukemia_With_t(15;17)(q22;q12)|Adult_Acute_Myeloid_Leukemia_With_t(16;16)(p13;q22)|Adult_Acute_Myelomonocytic_Leukemia_(M4)|Childhood_Acute_Basophilic_Leukemia|Childhood_Acute_Eosinophilic_Leukemia|Childhood_Acute_Erythroleukemia_(M6)|Childhood_Acute_Megakaryocytic_Leukemia_(M7)|Childhood_Acute_Minimally_Differentiated_Myeloid_Leukemia_(M0)|Childhood_Acute_Monoblastic_Leukemia_(M5a)|Childhood_Acute_Monocytic_Leukemia_(M5b)|Childhood_Acute_Myeloblastic_Leukemia_With_Maturation_(M2)|Childhood_Acute_Myeloblastic_Leukemia_Without_Maturation_(M1)|Childhood_Acute_Myelomonocytic_Leukemia_(M4)|Recurrent_Adult_Acute_Myeloid_Leukemia|Recurrent_Childhood_Acute_Myeloid_Leukemia|Secondary_Acute_Myeloid_Leukemia|,idarubicin|cytarabine|bortezomib|etoposide|laboratory_biomarker_analysis|,1,20,other_events,arm3,Bortezomib 1.3 mg/m2-assess Efficacy High Anthracycline Exp,1,20
Allergic_reaction,Immune_system_disorders,NCT00667251,https://clinicaltrials.gov/show/NCT00667251,Breast_Cancer,trastuzumab|docetaxel|lapatinib_ditosylate|paclitaxel|,74,647,other_events,arm1,Trastuzumab,43,325
Allergic_reaction,Immune_system_disorders,NCT00667251,https://clinicaltrials.gov/show/NCT00667251,Breast_Cancer,trastuzumab|docetaxel|lapatinib_ditosylate|paclitaxel|,74,647,other_events,arm0,Lapatinib,31,322
Allergic_Reaction,General_disorders,NCT00670982,https://clinicaltrials.gov/show/NCT00670982,Breast_Cancer,bevacizumab|vinorelbine|trastuzumab|,2,29,other_events,arm0,All Study Participants,2,29
Allergic_reaction,Immune_system_disorders,NCT00679354,https://clinicaltrials.gov/show/NCT00679354,Childhood_High-grade_Cerebellar_Astrocytoma|Childhood_High-grade_Cerebral_Astrocytoma|Recurrent_Childhood_Anaplastic_Astrocytoma|Recurrent_Childhood_Anaplastic_Oligoastrocytoma|Recurrent_Childhood_Anaplastic_Oligodendroglioma|Recurrent_Childhood_Brain_Tumor|Recurrent_Childhood_Cerebellar_Astrocytoma|Recurrent_Childhood_Cerebral_Astrocytoma|Recurrent_Childhood_Glioblastoma|Recurrent_Childhood_Visual_Pathway_and_Hypothalamic_Glioma|,cilengitide|laboratory_biomarker_analysis|pharmacological_study|,1,29,other_events,arm0,Treatment (Cilengitide),1,29
Allergic_Reaction,Immune_system_disorders,NCT00687297,https://clinicaltrials.gov/show/NCT00687297,Lung_Cancer|Non_Small_Cell_Lung_Cancer|,vandetanib_induction|Docetaxel|Carboplatin|Placebo|Vandetanib_maintenance|,3,157,serious_events,arm2,All Treated Patients - Induction,3,157
Allergic_Reaction,Eye_disorders,NCT00710905,https://clinicaltrials.gov/show/NCT00710905,Cataract,AcrySof_ReSTOR_Aspheric_IOL_models_SN6AD1_and_SN6AD3,1,50,other_events,arm0,ReSTOR,1,50
Allergic_reaction,Immune_system_disorders,NCT00720083,https://clinicaltrials.gov/show/NCT00720083,Head_and_Neck_Cancer,cisplatin|vandetanib|radiation_therapy|,1,16,serious_events,arm0,RT+ Cisplatin,1,16
Allergic_Reaction,Immune_system_disorders,NCT00741988,https://clinicaltrials.gov/show/NCT00741988,Non-Small_Cell_Lung_Cancer,Ixabepilone|Carboplatin|Bevacizumab|,1,40,serious_events,arm1,Ixabepilone/Carboplatin/Bevacizumab,1,40
Allergic_reaction,Immune_system_disorders,NCT00744874,https://clinicaltrials.gov/show/NCT00744874,Paroxysmal_Atrial_Fibrillation,RF_Ablation_procedure,1,55,other_events,arm0,Ablated Participants,1,55
allergic_reaction,Immune_system_disorders,NCT00760838,https://clinicaltrials.gov/show/NCT00760838,Asthma,Azithromycin_250_mg|Placebo|,3,109,other_events,arm0,Placebo,1,54
allergic_reaction,Immune_system_disorders,NCT00760838,https://clinicaltrials.gov/show/NCT00760838,Asthma,Azithromycin_250_mg|Placebo|,3,109,other_events,arm1,Azithromycin,2,55
allergic_reaction,General_disorders,NCT00765895,https://clinicaltrials.gov/show/NCT00765895,Idiopathic_Gastroparesis,Nortriptyline_Hydrochloride|Placebo_(for_nortriptyline)|,1,65,serious_events,arm0,Nortriptyline,1,65
Allergic_reaction,Immune_system_disorders,NCT00768144,https://clinicaltrials.gov/show/NCT00768144,Ovarian_Cancer|Fallopian_Tube_Cancer|Peritoneal_Cancer|,Sunitinib,1,36,serious_events,arm0,Sunitinib,1,36
Allergic_reaction,Immune_system_disorders,NCT00769314,https://clinicaltrials.gov/show/NCT00769314,Herpes_Labialis,Acyclovir_Lauriad|Placebo|,1,397,serious_events,arm1,Placebo Group,1,397
Allergic_reaction,Injury_poisoning_and_procedural_complications,NCT00781365,https://clinicaltrials.gov/show/NCT00781365,Hypertension,Telemonitors_and_pharmacy_management,1,222,other_events,arm0,Usual Care,1,222
Allergic_reaction,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,11,369,serious_events,arm0,Sorafenib (Nexavar BAY43-9006),1,123
Allergic_reaction,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,11,369,other_events,arm1,Placebo,3,123
Allergic_reaction,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,11,369,other_events,arm0,Sorafenib (Nexavar BAY43-9006),7,123
ALLERGIC_REACTION,Immune_system_disorders,NCT00825734,https://clinicaltrials.gov/show/NCT00825734,Metastatic_Breast_Cancer,Sorafenib|Ixabepilone|,10,76,other_events,arm0,Dose Level 1a,10,76
Allergic_reaction,Immune_system_disorders,NCT00831844,https://clinicaltrials.gov/show/NCT00831844,Adult_Rhabdomyosarcoma|Adult_Synovial_Sarcoma|Childhood_Hepatoblastoma|Childhood_Synovial_Sarcoma|Previously_Treated_Childhood_Rhabdomyosarcoma|Recurrent_Adrenocortical_Carcinoma|Recurrent_Adult_Soft_Tissue_Sarcoma|Recurrent_Childhood_Liver_Cancer|Recurrent_Childhood_Rhabdomyosarcoma|Recurrent_Childhood_Soft_Tissue_Sarcoma|Recurrent_Ewing_Sarcoma/Peripheral_Primitive|Neuroectodermal_Tumor|Recurrent_Neuroblastoma|Recurrent_Osteosarcoma|Recurrent_Retinoblastoma|Recurrent_Wilms_Tumor_and_Other_Childhood_Kidney_Tumors|,cixutumumab|laboratory_biomarker_analysis|,1,10,other_events,arm6,Grp 7-Neuroblastoma With Measurable Disease,1,10
Allergic_reaction,Immune_system_disorders,NCT00841204,https://clinicaltrials.gov/show/NCT00841204,Precancerous_Condition,sulindac|placebo|laboratory_biomarker_analysis|,3,50,other_events,arm0,Sulindac,1,25
Allergic_reaction,Immune_system_disorders,NCT00841204,https://clinicaltrials.gov/show/NCT00841204,Precancerous_Condition,sulindac|placebo|laboratory_biomarker_analysis|,3,50,other_events,arm1,Placebo,2,25
Allergic_reaction,Immune_system_disorders,NCT00846027,https://clinicaltrials.gov/show/NCT00846027,Breast_Cancer,Bevacizumab|Paclitaxel|Gemcitabine|,3,164,other_events,arm0,Bevacizumab + Paclitaxel + Gemcitabine,1,82
Allergic_reaction,Immune_system_disorders,NCT00849121,https://clinicaltrials.gov/show/NCT00849121,Prostate_Cancer,pTVG-HP_with_rhGM-CSF|pTVG-HP_with_rhGM-CSF|,3,17,other_events,arm1,2: pTVG-HP With rhGM-CSF Variable Dosing Post Week 12,2,9
Allergic_reaction,Immune_system_disorders,NCT00849121,https://clinicaltrials.gov/show/NCT00849121,Prostate_Cancer,pTVG-HP_with_rhGM-CSF|pTVG-HP_with_rhGM-CSF|,3,17,other_events,arm0,1: pTVG-HP With rhGM-CSF Every 3 Months Post Week 12,1,8
Allergic_reaction,Skin_and_subcutaneous_tissue_disorders,NCT00853593,https://clinicaltrials.gov/show/NCT00853593,Heart_Failure,Pacing_Lead,1,197,serious_events,arm0,Model 4396 LV Lead,1,197
Allergic_reaction,Immune_system_disorders,NCT00859937,https://clinicaltrials.gov/show/NCT00859937,High-grade_Salivary_Gland_Mucoepidermoid_Carcinoma|Low-grade_Salivary_Gland_Mucoepidermoid_Carcinoma|Recurrent_Salivary_Gland_Cancer|Salivary_Gland_Acinic_Cell_Tumor|Salivary_Gland_Adenocarcinoma|Salivary_Gland_Adenoid_Cystic_Carcinoma|Salivary_Gland_Anaplastic_Carcinoma|Salivary_Gland_Malignant_Mixed_Cell_Type_Tumor|Salivary_Gland_Poorly_Differentiated_Carcinoma|Salivary_Gland_Squamous_Cell_Carcinoma|Stage_IV_Salivary_Gland_Cancer|,dasatinib|laboratory_biomarker_analysis|,2,40,other_events,arm0,Adenoid Cystic Carcinoma,2,40
Allergic_reaction,Immune_system_disorders,NCT00863746,https://clinicaltrials.gov/show/NCT00863746,Carcinoma|Non-Small-Cell_Lung|,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,1,346,serious_events,arm0,Sorafenib (Nexavar BAY43-9006),1,346
ALLERGIC_REACTION,Immune_system_disorders,NCT00866905,https://clinicaltrials.gov/show/NCT00866905,Breast_Cancer,Ixabepilone|Cyclophosphamide|,10,167,other_events,arm0,Ixabepilone/Cyclophosphamide,10,167
Allergic_reaction,Immune_system_disorders,NCT00880334,https://clinicaltrials.gov/show/NCT00880334,Transitional_Cell_Carcinoma|Bladder_Cancer|,Docetaxel|Zactima|Placebo|,1,72,serious_events,arm1,Placebo and Docetaxel,1,72
Allergic_Reaction,Immune_system_disorders,NCT00883675,https://clinicaltrials.gov/show/NCT00883675,Non-small_Cell_Lung_Cancer,Docetaxel-Carboplatin,4,133,serious_events,arm0,Treatment,4,133
ALLERGIC_REACTION,Immune_system_disorders,NCT00887575,https://clinicaltrials.gov/show/NCT00887575,Breast_Cancer,Paclitaxel|Carboplatin|Sunitinib|,4,41,other_events,arm0,Dose Level I,4,41
Allergic_reaction,General_disorders,NCT00890656,https://clinicaltrials.gov/show/NCT00890656,Acute_Lymphoblastic_Leukemia,Cyclophosphamide_(CTX)|Vincristine|Doxorubicin|Decadron|G-CSF|Methotrexate_(MTX)|Ara-C|Pegaspargase|,2,90,serious_events,arm0,Augmented Hyper-CVAD,2,90
Allergic_reaction,General_disorders,NCT00893997,https://clinicaltrials.gov/show/NCT00893997,Leukemia|Myelodysplastic_Syndrome|,PR-1_vaccine,2,20,other_events,arm0,PR-1 Vaccine,1,10
Allergic_reaction,General_disorders,NCT00893997,https://clinicaltrials.gov/show/NCT00893997,Leukemia|Myelodysplastic_Syndrome|,PR-1_vaccine,2,20,serious_events,arm0,PR-1 Vaccine,1,10
allergic_reaction,Immune_system_disorders,NCT00895934,https://clinicaltrials.gov/show/NCT00895934,Adult_Acute_Megakaryoblastic_Leukemia_(M7)|Adult_Acute_Minimally_Differentiated_Myeloid_Leukemia_(M0)|Adult_Acute_Monoblastic_Leukemia_(M5a)|Adult_Acute_Monocytic_Leukemia_(M5b)|Adult_Acute_Myeloblastic_Leukemia_With_Maturation_(M2)|Adult_Acute_Myeloblastic_Leukemia_Without_Maturation_(M1)|Adult_Acute_Myeloid_Leukemia_With_11q23_(MLL)_Abnormalities|Adult_Acute_Myeloid_Leukemia_With_Inv(16)(p13;q22)|Adult_Acute_Myeloid_Leukemia_With_t(16;16)(p13;q22)|Adult_Acute_Myeloid_Leukemia_With_t(8;21)(q22;q22)|Adult_Acute_Myelomonocytic_Leukemia_(M4)|Adult_Erythroleukemia_(M6a)|Adult_Pure_Erythroid_Leukemia_(M6b)|Recurrent_Adult_Acute_Myeloid_Leukemia|,vorinostat|gemtuzumab_ozogamicin|azacitidine|,2,43,other_events,arm1,Phase 2/Selected Dose,2,43
Allergic_reaction,General_disorders,NCT00906425,https://clinicaltrials.gov/show/NCT00906425,Jaw_Edentulous_Partially,Straumann_Bone_Level_Implant,1,73,other_events,arm0,Submerged Healing,1,73
Allergic_reaction,Immune_system_disorders,NCT00924066,https://clinicaltrials.gov/show/NCT00924066,Cervical_Carcinoma|Cervical_Adenocarcinoma|Cervical_Adenosquamous_Carcinoma|Cervical_Carcinoma_Non-SquamousType|,Ixempra_(Ixabepilone_(BMS-247550)_),3,41,other_events,arm0,Adverse Events for Squamous and Non-squamous Participants,3,41
Allergic_reaction,General_disorders,NCT00945139,https://clinicaltrials.gov/show/NCT00945139,Ovarian_Cancer,Doxil|Avastin|,4,46,other_events,arm0,Doxil (PLD) + Avastin (Bevacizumab),4,46
Allergic_Reaction,Immune_system_disorders,NCT00955721,https://clinicaltrials.gov/show/NCT00955721,Cholangiocarcinoma|Biliary_Tract_Cancer|Gallbladder_Cancer|,Gemcitabine|Oxaliplatin|Sorafenib|,2,9,other_events,arm0,Phase 1,2,9
Allergic_Reaction,Surgical_and_medical_procedures,NCT00959374,https://clinicaltrials.gov/show/NCT00959374,Breast_Ptosis|Obesity|,V-Loc_180/90_Wound_Closure_Device|3-0_Monocryl_Absorbable_Sutures|,1,229,serious_events,arm3,Non-protocol Incision or Systemic Events,1,229
Allergic_reaction,Immune_system_disorders,NCT00965250,https://clinicaltrials.gov/show/NCT00965250,Thymoma|Thymic_Carcinoma|Thymic_Carcinoid|Thymic_Neuroendocrine_Tumors|,IMC-12,2,49,other_events,arm0,IMC-A12 Monotherapy in Patients,2,49
ALLERGIC_REACTION,Immune_system_disorders,NCT00972205,https://clinicaltrials.gov/show/NCT00972205,Cervical|Ovarian|Lung|Breast|Renal|,paclitaxel|CBT-1(Registered_Trademark)|Tc_99m_sestamibi|,1,12,other_events,arm0,Paclitaxel and CBT-1 to Treat Solid Tumors,1,12
Allergic_reaction,Immune_system_disorders,NCT00984282,https://clinicaltrials.gov/show/NCT00984282,Thyroid_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,1,207,serious_events,arm0,Sorafenib (Double Blind Only),1,207
Allergic_reaction,Immune_system_disorders,NCT00986674,https://clinicaltrials.gov/show/NCT00986674,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,cixutumumab|carboplatin|paclitaxel|cetuximab|,1,48,serious_events,arm2,Arm III (Carboplatin Paclitaxel Cetuximab Cixutumumab),1,48
Allergic_Reaction,General_disorders,NCT01082939,https://clinicaltrials.gov/show/NCT01082939,Chronic_Lymphocytic_Leukemia,Fludarabine|Cyclophosphamide|Alemtuzumab|Rituximab|,1,80,serious_events,arm0,CFAR,1,80
Allergic_reaction,Immune_system_disorders,NCT01091259,https://clinicaltrials.gov/show/NCT01091259,Ovarian_Cancer|Fallopian_Tube_Cancer|Primary_Peritoneal_Carcinoma|,Irinotecan|Bevacizumab|,1,29,other_events,arm0,Irinotecan With Bevacizumab,1,29
Allergic_reaction,Immune_system_disorders,NCT01093222,https://clinicaltrials.gov/show/NCT01093222,Extrahepatic_Bile_Duct_Adenocarcinoma|Gallbladder_Adenocarcinoma|Gallbladder_Adenocarcinoma_With_Squamous_Metaplasia|Hilar_Cholangiocarcinoma|Recurrent_Extrahepatic_Bile_Duct_Carcinoma|Recurrent_Gallbladder_Carcinoma|Undifferentiated_Gallbladder_Carcinoma|Unresectable_Extrahepatic_Bile_Duct_Carcinoma|Unresectable_Gallbladder_Carcinoma|,Erlotinib_Hydrochloride|Sorafenib_Tosylate|,1,34,serious_events,arm0,Sorafenib and Erlotinib,1,34
Allergic_reaction,General_disorders,NCT01100242,https://clinicaltrials.gov/show/NCT01100242,Metastatic_Renal_Cell_Carcinoma,Velcade_and_Sorafenib,1,17,other_events,arm0,VELCADE and Sorafenib,1,17
Allergic_reaction,Immune_system_disorders,NCT01100931,https://clinicaltrials.gov/show/NCT01100931,NSCLC|Solid_Tumors|,YM155|Carboplatin|Paclitaxel|,3,19,other_events,arm1,Phase II,3,19
Allergic_reaction,Immune_system_disorders,NCT01103323,https://clinicaltrials.gov/show/NCT01103323,Metastatic_Colorectal_Cancer,Regorafenib_(Stivarga_BAY73-4506)|Placebo|Best_Supportive_Care_(BSC)|,2,500,serious_events,arm0,Regorafenib (BAY73-4506)+BSC,2,500
Allergic_reaction,Immune_system_disorders,NCT01113632,https://clinicaltrials.gov/show/NCT01113632,Chronic_Lymphocytic_Leukemia|Small_Lymphocytic_Lymphoma|,Ofatumumab,30,77,other_events,arm0,Ofatumumab 1000mg,14,33
Allergic_reaction,Immune_system_disorders,NCT01113632,https://clinicaltrials.gov/show/NCT01113632,Chronic_Lymphocytic_Leukemia|Small_Lymphocytic_Lymphoma|,Ofatumumab,30,77,other_events,arm1,Ofatumumab 2000mg,16,44
Allergic_reaction,Immune_system_disorders,NCT01117623,https://clinicaltrials.gov/show/NCT01117623,Neoplasm,Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_20_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_40_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_100_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_120_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_140_mg|HCC_Child-Pugh_A_expansion_cohort:_Regorafenib_100_mg|HCC_Child-Pugh_B_expansion_cohort:_Regorafenib_100_mg|NSCLC_expansion_cohort:_Regorafenib_100_mg|,2,69,other_events,arm4,Escalation Cohort: Regorafenib (Stivarga BAY73-4506) 140 mg,1,10
Allergic_reaction,Immune_system_disorders,NCT01117623,https://clinicaltrials.gov/show/NCT01117623,Neoplasm,Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_20_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_40_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_100_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_120_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_140_mg|HCC_Child-Pugh_A_expansion_cohort:_Regorafenib_100_mg|HCC_Child-Pugh_B_expansion_cohort:_Regorafenib_100_mg|NSCLC_expansion_cohort:_Regorafenib_100_mg|,2,69,other_events,arm2,Regorafenib (Stivarga BAY73-4506) 100 mg,1,59
Allergic_reaction,Immune_system_disorders,NCT01125917,https://clinicaltrials.gov/show/NCT01125917,Back_Pain_Lower_Back_Chronic,Buprenorphine_transdermal_patch|Buprenorphine_transdermal_patch|Buprenorphine_transdermal_patch|,1,354,serious_events,arm0,Total BTDS 5 10 20,1,354
Allergic_reaction,Immune_system_disorders,NCT01132547,https://clinicaltrials.gov/show/NCT01132547,Cancer,cyproheptadine_hydrochloride|placebo|,1,9,other_events,arm0,Arm I Cyproheptadine Hydrochloride,1,9
Allergic_reaction,Immune_system_disorders,NCT01134614,https://clinicaltrials.gov/show/NCT01134614,Recurrent_Melanoma|Stage_III_Melanoma|Stage_IV_Melanoma|,ipilimumab|sargramostim|,1,118,serious_events,arm0,Arm A (Ipilimumab and Sargramostim),1,118
Allergic_reaction,Immune_system_disorders,NCT01140646,https://clinicaltrials.gov/show/NCT01140646,Healthy_no_Evidence_of_Disease|Hot_Flashes|,S-adenosyl-L-methionine_disulfate_p-toluene-sulfonate|questionnaire_administration|quality-of-life_assessment|,3,45,other_events,arm0,SAMe,3,45
Allergic_reaction,Immune_system_disorders,NCT01145495,https://clinicaltrials.gov/show/NCT01145495,Stage_II_Grade_1_Contiguous_Follicular_Lymphoma|Stage_II_Grade_1_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_3_Contiguous_Follicular_Lymphoma|Stage_II_Grade_3_Non-Contiguous_Follicular_Lymphoma|Stage_III_Grade_1_Follicular_Lymphoma|Stage_III_Grade_2_Follicular_Lymphoma|Stage_III_Grade_3_Follicular_Lymphoma|Stage_IV_Grade_1_Follicular_Lymphoma|Stage_IV_Grade_2_Follicular_Lymphoma|Stage_IV_Grade_3_Follicular_Lymphoma|,Laboratory_Biomarker_Analysis|Lenalidomide|Rituximab|,6,126,serious_events,arm0,Treatment (Lenalidomide Rituximab),1,63
Allergic_reaction,Immune_system_disorders,NCT01145495,https://clinicaltrials.gov/show/NCT01145495,Stage_II_Grade_1_Contiguous_Follicular_Lymphoma|Stage_II_Grade_1_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_3_Contiguous_Follicular_Lymphoma|Stage_II_Grade_3_Non-Contiguous_Follicular_Lymphoma|Stage_III_Grade_1_Follicular_Lymphoma|Stage_III_Grade_2_Follicular_Lymphoma|Stage_III_Grade_3_Follicular_Lymphoma|Stage_IV_Grade_1_Follicular_Lymphoma|Stage_IV_Grade_2_Follicular_Lymphoma|Stage_IV_Grade_3_Follicular_Lymphoma|,Laboratory_Biomarker_Analysis|Lenalidomide|Rituximab|,6,126,other_events,arm0,Treatment (Lenalidomide Rituximab),5,63
Allergic_reaction,Immune_system_disorders,NCT01160484,https://clinicaltrials.gov/show/NCT01160484,Multiple_Myeloma,DVD-R,1,40,serious_events,arm0,DVD-R Single Arm,1,40
Allergic_Reaction,Immune_system_disorders,NCT01162733,https://clinicaltrials.gov/show/NCT01162733,Infectious_Disease,Vancomycin|Vancomycin|,4,99,other_events,arm0,Study Drug 1,2,49
Allergic_Reaction,Immune_system_disorders,NCT01162733,https://clinicaltrials.gov/show/NCT01162733,Infectious_Disease,Vancomycin|Vancomycin|,4,99,other_events,arm1,Study Drug 2,2,50
Allergic_reaction,Immune_system_disorders,NCT01190527,https://clinicaltrials.gov/show/NCT01190527,Non-Small_Cell_Lung_Cancer,FDG-PET,1,42,serious_events,arm0,Adaptive Radiation,1,42
Allergic_reaction,Immune_system_disorders,NCT01206140,https://clinicaltrials.gov/show/NCT01206140,Recurrent_Adult_Soft_Tissue_Sarcoma|Stage_III_Adult_Soft_Tissue_Sarcoma|Stage_IV_Adult_Soft_Tissue_Sarcoma|,Laboratory_Biomarker_Analysis|Selumetinib|Temsirolimus|,1,35,other_events,arm1,Arm II (Selumetinib and Temsirolimus),1,35
Allergic_reaction,Immune_system_disorders,NCT01207102,https://clinicaltrials.gov/show/NCT01207102,Metastatic_Breast_Cancer,Abraxane|Carboplatin|,3,20,other_events,arm0,Abraxane Carboplatin,2,10
Allergic_reaction,Immune_system_disorders,NCT01207102,https://clinicaltrials.gov/show/NCT01207102,Metastatic_Breast_Cancer,Abraxane|Carboplatin|,3,20,serious_events,arm0,Abraxane Carboplatin,1,10
ALLERGIC_REACTION,Immune_system_disorders,NCT01282294,https://clinicaltrials.gov/show/NCT01282294,Tibia_Fractures,ETN_PROtect,2,99,other_events,arm0,ETN PROtect,2,99
Allergic_reaction,Immune_system_disorders,NCT01289821,https://clinicaltrials.gov/show/NCT01289821,Colorectal_Neoplasms,Regorafenib_(Stivarga_BAY73-4506)|Oxaliplatin|Folinic_acid|5-FU_(mFOLFOX6)|,4,53,other_events,arm0,Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6),4,53
Allergic_Reaction,Immune_system_disorders,NCT01290913,https://clinicaltrials.gov/show/NCT01290913,Peanut_Allergy,Omalizumab,10,13,other_events,arm0,Omalizumab Oral Desensitization,10,13
Allergic_reaction,Immune_system_disorders,NCT01303835,https://clinicaltrials.gov/show/NCT01303835,Malignant_Glioma,LDN|Placebo|,2,56,other_events,arm1,Placebo,2,56
Allergic_reaction,Immune_system_disorders,NCT01313078,https://clinicaltrials.gov/show/NCT01313078,Ovarian_Neoplasms|Fallopian_Tube_Neoplasms|Primary_Peritoneal_Neoplasms|,Pegylated_L-Asparaginase,1,4,serious_events,arm0,Pegaspargase in Women With Cancer,1,4
Allergic_reaction,Immune_system_disorders,NCT01334515,https://clinicaltrials.gov/show/NCT01334515,Recurrent_Neuroblastoma,hu14.18-IL2_fusion_protein|isotretinoin|sargramostim|laboratory_biomarker_analysis|,2,36,other_events,arm1,Disease Evaluable Only by I-MIBG or BM Histology,2,36
Allergic_reaction,Investigations,NCT01351090,https://clinicaltrials.gov/show/NCT01351090,Postoperative_Pain,Ketorolac_tromethamine|Ketorolac_tromethamine|Placebo|,1,42,serious_events,arm1,Ketorolac IN 30 mg,1,42
Allergic_reaction,Investigations,NCT01402063,https://clinicaltrials.gov/show/NCT01402063,Glioblastoma_Multiforme,PPX_(CT2103)|Temozolomide|,1,18,other_events,arm1,Radiation + Temozolomide and Maintenance,1,18
Allergic_reaction,Immune_system_disorders,NCT01447927,https://clinicaltrials.gov/show/NCT01447927,Barrett_Esophagus|Esophageal_Cancer|,metformin_hydrochloride|placebo|,1,36,other_events,arm0,Placebo,1,36
Allergic_reaction,Immune_system_disorders,NCT01484652,https://clinicaltrials.gov/show/NCT01484652,Pain_Postoperative|Bunion|,COV795|Placebo|,1,94,serious_events,arm1,Placebo,1,94
Allergic_Reaction,Immune_system_disorders,NCT01531998,https://clinicaltrials.gov/show/NCT01531998,Myeloma,Lenalidomide|Bortezomib|Siltuximab|Dexamethasone|Questionnaires|,1,11,other_events,arm0,Siltuximab + Bortezomib + Lenalidomide,1,11
Allergic_reaction,Immune_system_disorders,NCT01557283,https://clinicaltrials.gov/show/NCT01557283,Plaque_Psoriasis_Patients,Enbrel_treatment,1,138,other_events,arm0,Etanercept,1,138
Allergic_reaction,Immune_system_disorders,NCT01557959,https://clinicaltrials.gov/show/NCT01557959,Adenocarcinoma_of_the_Lung|Adenosquamous_Cell_Lung_Cancer|Bronchoalveolar_Cell_Lung_Cancer|Large_Cell_Lung_Cancer|Non-small_Cell_Lung_Cancer|Recurrent_Non-small_Cell_Lung_Cancer|Squamous_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,cisplatin|pegfilgrastim|erlotinib_hydrochloride|laboratory_biomarker_analysis|polymorphism_analysis|pharmacogenomic_studies|genetic_linkage_analysis|docetaxel|,44,88,serious_events,arm0,Treatment (Chemo Chemoprotection Antiangiogenesis Therapy),2,44
Allergic_reaction,Immune_system_disorders,NCT01557959,https://clinicaltrials.gov/show/NCT01557959,Adenocarcinoma_of_the_Lung|Adenosquamous_Cell_Lung_Cancer|Bronchoalveolar_Cell_Lung_Cancer|Large_Cell_Lung_Cancer|Non-small_Cell_Lung_Cancer|Recurrent_Non-small_Cell_Lung_Cancer|Squamous_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,cisplatin|pegfilgrastim|erlotinib_hydrochloride|laboratory_biomarker_analysis|polymorphism_analysis|pharmacogenomic_studies|genetic_linkage_analysis|docetaxel|,44,88,other_events,arm0,Treatment (Chemo Chemoprotection Antiangiogenesis Therapy),42,44
Allergic_reaction,Immune_system_disorders,NCT01623869,https://clinicaltrials.gov/show/NCT01623869,Adult_Angiosarcoma|Recurrent_Adult_Soft_Tissue_Sarcoma|Stage_III_Adult_Soft_Tissue_Sarcoma|Stage_IV_Adult_Soft_Tissue_Sarcoma|,Laboratory_Biomarker_Analysis|Trebananib|,1,16,other_events,arm0,Treatment (Trebananib),1,16
Allergic_reaction,Immune_system_disorders,NCT01656031,https://clinicaltrials.gov/show/NCT01656031,Leukemia,clofarabine|cytarabine|,2,39,serious_events,arm0,High-Dose Cytarabine and Clofarabine,2,39
Allergic_reaction,Immune_system_disorders,NCT01681368,https://clinicaltrials.gov/show/NCT01681368,Epithelial_Ovarian_Cancer|Peritoneal_Neoplasms|Fallopian_Tube_Neoplasms|,Birinapant_(TL32711),1,11,other_events,arm0,Birinapant for Advanced OvarianFallopian Tube & Peritoneal Ca,1,11
Allergic_reaction,Immune_system_disorders,NCT01885559,https://clinicaltrials.gov/show/NCT01885559,Kidney_Polycystic,Lisinopril|Telmisartan|Placebo|,1,242,serious_events,arm0,ACE-I + Placebo,1,242
Allergic_reaction,Immune_system_disorders,NCT01996332,https://clinicaltrials.gov/show/NCT01996332,Non-Small_Cell_Lung_Cancer,erlotinib_[Tarceva],3,1797,other_events,arm0,Erlotinib 150 mg/Day,3,1797
Allergic_reaction,Immune_system_disorders,NCT02127372,https://clinicaltrials.gov/show/NCT02127372,Non-small_Cell_Lung_Cancer,Docetaxel_Cisplatin_and_STI571|Docetaxel|Cisplatin|,2,28,other_events,arm1,Phase 2,2,28